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ABSTRACT 
We are currently facing a global epidemic of obesity, which poses a great challenge 
for the global health. Insulin resistance is the common soil that links obesity and type 
2 diabetes. Whereas most lifestyle interventions fail, bariatric surgery has been a 
powerful weapon in the battle against obesity. Preclinical data have shown that the 
brain may directly control the determinants of glucose tolerance, namely insulin 
sensitivity and insulin secretion. We used positron emission tomography, to study 
whether brain metabolism assessed as brain glucose and/or brain fatty acid uptake is 
related to the endogenous glucose production (EGP), and ß-cell function. Moreover, 
we addressed whether there are differences in brain fatty acid uptake between 
morbidly obese and lean individuals as well as the effect of significant weight loss 
induced by bariatric surgery. Finally, we investigated whether brain substrate 
handling predicted any metabolic outcome at follow-up.  
We found that in morbidly obese subjects brain glucose uptake (BGU) correlated 
positively with EGP, and that this association remained significant also six months 
after surgery. On the contrary, there was no such association in the lean subjects. In 
52 non-diabetic subjects to whom ß-cell modeling was performed, insulin-stimulated 
BGU correlated also with the basal insulin secretion, total insulin output and 
potentiation of glucose-stimulated insulin secretion. Contrastingly, in 15 patients 
with type 2 diabetes BGU and insulin secretion did not correlate, but there was a 
significant inverse correlation between BGU and potentiation. Cross-sectionally in 
34 studied women, brain fatty acid uptake (BFAU) also correlated negatively with 
potentiation, and similar trends were seen both in non-diabetics and diabetics.  
Finally, we found that, unlike in lean individuals, BFAU is increased in morbidly 
obese subjects, and that six months after bariatric surgery, BFAU remained 
unchanged. Baseline BGU and baseline BFAU predicted worse glucose control at 
two-year follow-up after bariatric surgery.  
In conclusion, this thesis work shows that brain substrate handling differs in 
obese and lean individuals and that brain metabolism may be a direct way of 
controlling whole-body homeostasis in humans. Moreover, in two different datasets, 
increased brain substrate uptake at baseline predicted worse metabolic outcome after 
bariatric surgery.  
KEYWORDS: endogenous glucose production, β-cell function, brain glucose 
uptake, brain fatty acid uptake, bariatric surgery, positron emission tomography   
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TIIVISTELMÄ 
Tämänhetkinen lihavuusepidemia asettaa valtavan maailmanlaajuisen terveys-
haasteen. Insuliiniresistenssi yhdistää lihavuuden tyypin 2 diabetekseen. Siinä missä 
elämäntapainterventiot useimmiten epäonnistuvat, lihavuusleikkaus on ollut tehokas 
ase lihavuuden vastaisessa taistelussa. Prekliinisten tutkimusten perusteella on 
osoitettu, että aivot voivat olla suoraan vastuussa insuliiniherkkyyden ja insuliini-
nerityksen säätelystä ja siten glukoositasapainosta. Tutkimme positroniemissio-
tomografian avulla, onko aivojen glukoosin tai rasvahappojen otto yhteydessä kehon 
glukoosintuotantoon tai β-solujen toimintaan ihmisillä. Lisäksi selvitimme, 
ennustaako aivojen ravintoaineiden käsittely aineenvaihduntaan liittyviä muuttujia 
leikkauksen jälkeisen seurantajakson aikana. 
Tutkimuksessa havaitsimme, että vaikeasti lihavilla tutkittavilla aivojen 
glukoosinotto korreloi positiivisesti kehon glukoosintuoton kanssa ja tämä yhteys 
säilyi myös 6 kk kuluttua leikkauksesta. Sitä vastoin normaalipainoisilla tutkittavilla 
tällaista yhteyttä ei havaittu. β-solujen toimintaa mallinnettiin 67:llä tutkittavalla. 
Analyysin perusteella aivojen glukoosinotolla oli positiivinen korrelaatio insuliinin 
perustilan tuotantoon, insuliinin kokonaistuotantoon sekä insuliinintuoton tehos-
tamiseen. Sen sijaan aivojen rasvahappojen otto korreloi negatiivisesti insuliinin-
tuoton tehostamiseen. 
Tutkimuksessa havaittiin lisäksi, että aivojen rasvahappojenotto oli lisääntynyt 
vaikeasti lihavilla tutkittavilla normaalipainoisiin verrattuna ja tämä ero säilyi myös 
6 kk leikkauksen jälkeen. Korkeampi aivojen glukoosin ja rasvahappojen otto ennen 
leikkausta ennusti huonompaa glukoositasapainoa 2 vuoden kuluttua leikkauksesta. 
Tässä väitöstyössä osoitettiin, että aivojen aineenvaihdunta voi suoraan säädellä 
koko kehon aineenvaihduntaa. Lisäksi osoitettiin kahdessa erillisessä aineistossa 
suuremman aivojen ravintoaineiden oton ennustavan huonompaa aineenvaihdunnan 
terveyttä lihavuusleikkauksen jälkeen. 
AVAINSANAT: endogeeninen glukoosin tuotanto, β-solujen toiminta, aivojen glu-
koosinotto, aivojen rasvahappojenotto, lihavuus, lihavuusleikkaus, positroniemissio-
tomografia  
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Abbreviations 
[18F]FDG [18F]2-fluoro-2-deoxy-D-glucose 
[18F]FTHA 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid 
Aβ amyloid beta  
AD Alzheimer disease 
AUC area under the curve 
BBB blood-brain barrier 
BGU brain glucose uptake 
BFAU brain fatty acid uptake 
BMI body mass index 
BS bariatric surgery 
CBF cerebral blood flow 
CMRO2  cerebral metabolic rate for oxygen 
CNS central nervous system 
Cp plasma concentration 
DIO diet-induced obesity 
EGP endogenous glucose production 
FDR false discovery rate 
FA fatty acids 
FATP  fatty-acid transporter 
FFA free fatty acids 
FLAIR fluid-attenuated inversion recovery 
FUR fractional uptake rate 
GFAP  glial fibrillary acidic protein 
GIP  glucose dependent insulinotropic polypeptide 
GIR glucose infusion rate 
GLP-1 glucagon-like peptide 1 
HFD high fat diet 
HGP hepatic glucose production 
ICC intraclass correlation coefficient 
ICV  into the third-cerebral-ventricle 
IFG impaired fasting glucose  
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IGF-1 insulin-like growth factor 1 
IGF-1R insulin-like growth factor 1 receptor 
IGT impaired glucose tolerance 
IQR interquartile range 
IR insulin receptor 
ISR insulin secretion rate 
IRS1 insulin receptor substrate 1 
Ki influx constant rate  
LSG laparoscopic Sleeve gastrectomy 
MAP  mitogen-activated protein  
MBH mediobasal hypothalamus 
MCT monocarboxylate transporters 
MNI  Montreal Neurological Institute 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
NGT normal glucose tolerance  
NMR nuclear magnetic resonance 
NIRKO neuron-specific IR knockout  
non-T2D subjects not affected by T2D 
OGTT oral glucose tolerance test 
PET positron emission tomography  
PI3K phosphatidylinositol-3-kinase 
Rd rate of disappearance 
ROI region of interest 
RYGB Roux-y gastric bypass 
SUV standardized uptake value 
SPM statistical parametric mapping 
T2D type 2 diabetes 
WHP waist-to-hip ratio 
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1 Introduction 
Obesity is a rapidly increasing public health problem. We are currently facing a 
global obesity epidemic and the number of overweight and obese adults is projected 
to be 1.35 billion and 573 million, respectively, by 2030 (Kelly et al., 2008). Obesity 
is a major public health burden since it associates with an enhanced risk of 
cardiovascular disease, type 2 diabetes (T2D), stroke, neurodegenerative diseases, 
and many types of cancer (Pugazhenthi et al., 2017; World Health 2018). Obesity is 
strongly related to insulin resistance and T2D (Vazquez et al., 2007). The term 
“diabesity” was coined to underline the close pathophysiological connection 
between the two conditions. 
Diet modification, and lifestyle intervention have proved to be only a weak arm 
in the fight against obesity, a condition of which the pathophysiology is much more 
complex than just overeating. Bariatric surgery, on the other hand, is the most 
powerful weapon in the battle against morbid obesity. As such, it is often used in a 
research setting in order to achieve rapid weight loss and marked improvement in 
insulin sensitivity.  
Positron emission tomography (PET) is considered, nowadays, the gold standard 
for measuring regional substrate utilization in humans. With the application of PET, 
measuring metabolism at the tissue level is possible. 
Previous studies from our centre using PET have shown that during euglycemic 
hyperinsulinemia obese subjects, and subjects with impaired glucose tolerance (IGT) 
have increased brain glucose uptake (BGU) compared to lean and normal glucose 
tolerant (NGT) individuals (Hirvonen et al., 2011; Tuulari et al., 2013). Even though 
this finding has been consolidated also from later studies from us and other groups 
in both animals and humans (Bahri et al., 2018; Latva-Rasku et al., 2017), its 
molecular mechanism remains unknown. A previous study from our centre also 
showed that brain fatty acid uptake is higher in subjects with metabolic syndrome 
(Karmi et al., 2010) than healthy, lean individuals.  
In the present thesis, we sought to determine whether brain substrate uptake in 
obese, insulin resistant subjects relates also to other parameters of whole-body 
homeostasis (insulin sensitivity, endogenous glucose production, insulin secretion 
and other parameters of ß-cell function), and whether this increased brain substrate 
Eleni Rebelos 
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uptake in insulin resistance can predict any metabolic outcome during follow-up. It 
is also worth mentioning that during the work performed for this PhD thesis, a novel 
idea has been conceived on the mechanism behind the increased BGU in 
obese/insulin resistant subjects. Even though such studies (on the mechanism) are 
not part of this PhD thesis, the study hypothesis is briefly described in this book.  
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2 Review of the Literature 
2.1 Obesity and Insulin Resistance 
Obesity is globally on the rise, more than 1.3 billion adults being overweight, and 
over 500 million being obese (Nguyen and El-Serag 2010). Obesity results in an 
increased risk for premature death and is the leading cause of a multitude of diseases: 
T2D, hypertension, dyslipidemia, asthma, arthritis and musculoskeletal disorders as 
well as many types of cancer (Mokdad et al., 2003). Obesity is also linked to an 
increased vulnerability to infectious diseases, such as the SARS-COV2, which 
caused the recent pandemic (Moriconi et al., 2020; Rebelos et al., 2020b).  
In 2011 there were approximately 366 million people with T2D, and this number 
is expected to rise to 552 million by 2030 (Whiting et al., 2011).  
The common link between obesity and T2D is insulin resistance. Initially, the ß-
cells are able to compensate for the decreased insulin sensitivity, by increasing 
insulin secretion. However, ultimately, the pancreas does not manage to cope with 
the increased needs of insulin secretion, and impairment in glucose tolerance ensues. 
Even though this is the classical understanding of the pathophysiology of T2D, there 
is also evidence that hyperinsulinemia, per se, may also exacerbate insulin resistance 
(Del Prato et al., 1994). Furthermore, epidemiological evidence suggests that 
hyperinsulinemia, independently of insulin resistance, is an independent risk 
indicator of future T2D (Weyer et al., 2000).  
2.2 Obesity, Type 2 Diabetes and 
Neurodegeneration  
Alzheimer disease (AD) is the primary cause of dementia, accounting for two thirds 
of all dementia cases. Currently, there are more than 35 million patients affected with 
AD worldwide (Pugazhenthi et al., 2017). 
Epidemiological studies have shown that obesity and T2D are risk factors for AD, 
and thus there are concerns that the incidence of AD could rise substantially in the 
following years, in line with the rise of obesity and T2D. A strong correlation between 
T2D and AD was first reported in the Rotterdam study, a large prospective study 
evaluating 6370 elderly subjects, which showed that patients with T2D have almost 
Eleni Rebelos 
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double the risk of dementia and AD (Ott et al., 1999). It has also been shown that body 
mass index (BMI) is associated with reduced brain volume in patients affected by AD 
(Ho et al., 2010). A meta-analysis reported that obesity and T2D significantly and 
independently increased the risk for AD in elderly individuals (Profenno et al., 2010). 
However, in that study, the obese and patients with T2D had a smaller risk for 
developing AD than persons carrying the APOE4 allele, a gene that is linked to 
increased risk for AD (Michaelson 2014). T2D seems to affect women less favorably 
than men, since diabetic women over 65 years of age were found to have a higher rate 
of developing AD than elderly men with T2D (Wang et al., 2012).  
Several studies have tried to evaluate the molecular links between AD and T2D. 
One suggestion has been the amylin receptor, as it is a target for both amylin and 
amyloid beta (Aβ) in the brain (Fu et al., 2013). Other studies have focused on the 
insulin effects on the brain, suggesting that decreased insulin action in the brain may 
have a role in the interplay between T2D and AD. More specifically, it has been 
shown that patients with AD have reduced expression and activation of the insulin 
receptor (IR), insulin-like growth factor 1 (IGF-1) receptor, and insulin receptor 
substrate 1 (IRS-1) proteins in the brain, and in the hippocampus and hypothalamus 
in particular (Steen et al. 2005). In line with this, in a small clinical trial it has been 
shown that intranasal insulin administration to patients with AD decreases the rates 
of cognitive dysfunction (Craft et al., 2012). 
2.3 Brain Insulin Receptors 
Insulin receptors and receptors of the IGF-1 are found throughout the brain. In the 
brain of mice, the insulin receptors are mainly expressed in the olfactory bulb, and 
to a lesser degree, in the cortex, the hippocampus, the hypothalamus, and the 
cerebellum (Zhao et al., 2004). In contrast, the IGF-1 receptor (IGF-1R) has the 
highest expression in the cortex, the hippocampus, and the thalamus, with only a 
moderate expression in the olfactory bulb, the hypothalamus, and the cerebellum 
(Fernandez and Torres-Aleman 2012).  
In addition to topographic differences in their distribution, the two receptors, also 
have different physiological functions. Studies on mice with neuron-specific IR 
knockout (NIRKO) have shown that these animals have normal brain size and 
development, but exhibit clearly pathologic metabolic phenotypes, such as obesity 
and insulin resistance (Bruning et al., 2000). On the other hand, knockout of the IGF-
1R in the brain results in reduced brain size, growth retardation, and behavioral 
changes (Kappeler et al., 2008).  
Insulin levels in the cerebrospinal fluid are approximately 25% of those in the 
blood and increase proportionally after meals or with peripheral insulin infusion 
(Woods et al., 2003). Insulin enters the brain either via circumventricular regions 
Review of the Literature 
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that lack a tight blood-brain barrier or through a receptor-mediated saturable 
transport system (Weindl and Sofroniew 1981). 
Areas such as the hypothalamus, which lack an effective barrier, allow rapid 
access to insulin. Indeed, studies have shown that following peripheral insulin 
injection rapid activation of insulin signaling in these regions occurs (Kleinridders 
et al., 2013). Interestingly, in lower organisms, like Drosophila, insulin-like peptides 
are primarily produced by neurons (Fernandez and Torres-Aleman 2012). Even 
though, until recently, there was no evidence that insulin is produced in the brains of 
mammals, a study that has been very recently published suggests that in mice, insulin 
is produced in some restricted areas of the brain (Lee et al., 2020). The 
(patho)physiological significance of brain derived insulin is under study. 
2.4 Central insulin effects on cognition, brain 
metabolism and whole-body homeostasis 
Insulin has several functions in the central nervous system (CNS). The main 
behavioral actions of insulin in the CNS consist of regulation of cognition and 
feeding. In lean individuals, intranasal insulin increases the activity of memory-
related areas (Kullmann et al., 2017; Marks et al., 2009).  
Insulin in the brain also affects the control of body temperature. It has been 
shown that injection of insulin or IGF-1 into the preoptic area can activate brown 
adipose tissue and induce hyperthermia and that this effect is lost in the NIRKO 
mouse, indicating that it is mediated by the insulin receptor (Sanchez-Alavez et al., 
2011). In humans, intranasal insulin administration has also been shown to enhance 
postprandial thermogenesis (Benedict et al., 2011). 
Regarding brain metabolism, it has been long thought that insulin does not affect 
brain glucose utilization. However, in the beginning of the second millennium a 
[18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET study showed that BGU is 
decreased when somatostatin infusion is given compared to baseline, suggesting that 
insulin levels contribute to brain glucose metabolism in humans (Bingham et al., 
2002). Later studies from our centre with the application of the euglycemic 
hyperinsulinemic clamp have shown that in the obese subjects and in subjects with 
impaired glucose tolerance (IGT), BGU is higher during the euglycemic 
hyperinsulinemic study than during the fasting state. Hence, when studying BGU 
during clamp, we have used the term “insulin-stimulated BGU”. Such an increase in 
BGU was not seen in the lean and normal glucose tolerant (NGT) subjects. It is 
important to note though that in both these studies, the groups of the lean and NGT 
subjects were small (N= 7 and 9, respectively), and thus it is unknown whether the 
effect of insulin on enhancing brain glucose uptake also in lean/NGT subjects was 
not seen merely because of lack of statistical power. In the same line, also in a PET 
Eleni Rebelos 
 16
study in minipigs an effect of insulin on increasing BGU from the fasting state was 
seen in these animals, a phenomenon which, however, also did not reach statistical 
significance (Bahri et al., 2018).  
One plausible explanation for the increased insulin-stimulated BGU in the obese 
subjects could be that this effect is driven by the higher circulating serum insulin 
typically seen in obese/insulin resistant subjects, because of decreased insulin 
clearance and higher insulin secretion. However, had this been the case, then the 
increased BGU should have been restricted in areas where the insulin sensitive 
glucose transporter GLUT4 is found and thus mainly restricted in the hypothalamus 
and the hippocampus (Williamson et al., 2012). However, the increases in BGU in 
the studies by Hirvonen et al. and Tuulari et al. are actually seen at the whole brain 
level, where mainly the insulin independent glucose transporters are present (GLUT1 
in astrocytes, and GLUT3 in neurons). Moreover, the insulin transport through the 
blood-brain barrier (BBB) has been described to be a saturable process. The plasma-
to-cerebrospinal fluid ratio of insulin has been described to be decreased in obesity 
(Kern et al., 2006). Still, the difference in BGU between obese and lean individuals 
is seen only during insulin stimulation, and not during the fasting state (Tuulari et 
al., 2013). Thus, clearly insulin plays a role, even though the mechanism is not yet 
understood.  
At the whole-body level, animal studies suggest that in contrast to peripheral 
insulin, CNS insulin elevates blood glucose levels, decreases food intake and 
increases energy expenditure (Banks et al., 1997). In line with this NIRKO mice 
exhibit mild obesity and insulin resistance (Bruning et al., 2000). Direct central 
insulin action also affects serum insulin levels, even though the results are diverging. 
It has been reported that insulin given directly into the lateral hypothalamus 
stimulates parasympathetic outflow to the pancreas, while injection of insulin into 
the ventromedial hypothalamus has the opposite effect (Oomura and Kita 1981). 
Hypothalamic insulin signaling is also needed for insulin suppression of hepatic 
glucose production (Okamoto et al., 2005). 
Recently it has also been shown that knock-out of the insulin receptor from 
astrocytes affects astroglial morphology (typically alterations in morphology are 
also followed by changes in function), reduces glucose sensing in specific 
hypothalamic neurons, alters systemic glucose homeostasis, and decreases BGU 
(Garcia-Caceres et al., 2016). Based on these findings the authors concluded that 
through insulin signaling astrocytes take part in CNS glucose sensing and that they 
are involved in controlling the systemic glucose metabolism (Garcia-Caceres et al., 
2016).  
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2.5 Brain glucose metabolism and determinants of 
brain glucose uptake 
The brain has a high demand of energy. Compared to the other organs, the brain 
consumes the highest amount of energy, which is approximately 20% of total body 
energy consumption, though it comprises only 2% of the typical human body mass 
(Mink et al., 1981). Most of the energy needed for the brain is used for sending and 
processing electrical signals across the brain’s circuits. Probably as a consequence 
of this the neurons were considered to use most of the glucose that is taken up by the 
brain, while glial cells including astrocytes were considered to consume only a little 
of the glucose entering the brain. However, this notion has been challenged based on 
the findings of a preclinical PET study, where it was shown that the [18F]FDG uptake 
in the brain was driven by astrocytes (Zimmer et al., 2017). This finding is in accord 
with what was originally proposed as the astrocyte neuron lactate shuttle (ANLS), 
whereby glutamate released by the neurons as neurotransmitter stimulates glucose 
uptake by astrocytes. Subsequently, astrocytes transform glucose into lactate, and 
provide lactate to the neurons (Pellerin and Magistretti 1994). However, this 
metabolic paradigm remains controversial (Diaz-Garcia et al., 2017). 
In recent years, most in vivo human studies assessing brain metabolism have been 
performed either during the postabsorptive state or during insulin administration. The 
mode of insulin administration may also vary: either the euglycemic hyperinsulinemic 
clamp technique can be applied or insulin can be given intranasally. Pancreatic clamps 
where also somatostatin is infused to block endogenous pancreatic secretions have also 
been used. The application of intranasal administration of insulin has the advantage of 
providing high doses of insulin directly to the brain. Spillover, i.e. insulin going also 
in the systemic circulation is usually minimal. Using intranasal insulin administration, 
pioneering studies at Tubingen University have shown that intranasal insulin 
suppresses EGP in lean, but not in overweight individuals (Heni et al., 2017) (this study 
will be further discussed later). 
We and other groups have addressed whether insulin resistance and T2D 
influence brain metabolic rates, assessed with [18F]FDG-PET. However there is 
inconsistency in the yielded results. Several studies have reported that insulin 
resistance (assessed with HOMA-IR) and prediabetes/early-onset T2D associate 
with cerebral hypometabolism in key areas that are affected in AD (Baker et al., 
2011). On the contrary, our group has previously shown that brain glucose uptake 
(BGU) during insulin clamp is higher in obese subjects and subjects with IGT 
compared to lean and NGT subjects, respectively (Hirvonen et al., 2011; Tuulari et 
al., 2013). Whereas differences during fasting BGU were not found between obese 
and lean subjects, the enhancement of BGU during insulin stimulation in obese and 
IGT subjects resulted in higher insulin-stimulated BGU in obese and IGT subjects 
than in lean and NGT subjects. Recently our group demonstrated that also subjects 
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with inherited insulin resistance (AKT-2 loss of function mutation, p.P50T/AKT2) 
had higher BGU during insulin-stimulation than age-matched controls (Latva-Rasku 
et al., 2017). This finding of increased brain glucose uptake in insulin resistance is 
“bizarre” if we consider that for instance in skeletal muscle obese subjects have 
lower glucose uptake than lean subjects in conditions of insulin stimulation. The 
molecular mechanism that is behind this “bizarre” characteristic of brain metabolism 
is thus far not understood. 
Other important determinants of brain glucose uptake –when assessed during 
fasting- are age, and gender. It is agreed that brain glucose uptake decreases with 
aging. Goyal et al. conducted a meta-analysis of PET studies performed to quantify 
brain metabolic rates of glucose, oxygen extraction (cerebral metabolic rate for 
oxygen: CMRO2), and perfusion (Cerebral blood flow: CBF) (Goyal et al., 2017). 
For subjects over 45 years old, they reported median values of fasting BGU as   ̴22 
µmol/100g/min, CMRO2 as ̴ 140 µmol/100g/min, and CBF as ̴ 44 mL/100g/min. 
The authors reported that with aging whereas brain glucose uptake decreases, brain 
oxygen extraction does not vary considerably. By coupling the glucose and oxygen 
extraction data, they concluded that this change in glucose metabolism with aging is 
largely due to loss of aerobic glycolysis, which represents the fraction of BGU that 
is not metabolized by oxidative phosphorylation (Goyal et al., 2017). Moreover, 
using PET imaging they further demonstrated that the regional topography of brain 
aerobic glycolysis changes significantly with normal aging. 
There are also significant differences between the two genders. Several 
differences in brain structure and metabolic demands have been reported between 
men and women; these include differences in synaptic density (Alonso-Nanclares et 
al., 2008) and in neocortical thickness (Pakkenberg and Gundersen 1997). Several 
reports have also reported higher CBF in women compared to men. Recently, it has 
also been shown that whereas women have higher CBF in the cortical regions than 
men, the difference is lost in aging women suggesting, that a plausible mediator for 
the higher CBF in women of reproductive age is estrogen. Regarding brain 
metabolism, brain glucose utilization is not clearly different at the whole brain level. 
It is higher in female rats than male rats in specific brain areas, such as the 
hypothalamic medial preoptic area, the ventromedial nucleus, the median eminence, 
and the superior colliculus among a few others, but only when the female rats are 
studied during the premetestrous or metestrous period of the estrous cycle (Bishop 
and Simpkins 1992). Moreover, ovariectomy significantly decreases brain glucose 
utilization (Le Foll et al., 2009), whereas ovariectomized rats, which received 
estrogen replacement showed a 20-30% increase in brain glucose utilization in most 
brain regions. All in all, these data suggest that estrogens up regulate brain glucose 
utilization and that their effect is not restricted only to areas where sex steroid 
receptors are expressed (Bishop and Simpkins 1992; Namba and Sokoloff 1984). 
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2.6 Brain fatty acid handling 
Lipids are an essential component of the brain both in terms of the structure of 
cellular membranes and in terms of the correct function of numerous cellular 
processes (Falomir-Lockhart et al., 2019). They make up approximately 50% of 
brain weight, which is the second highest lipid content after adipose tissue (Hamilton 
et al., 2007). It has been suggested that cerebral lipids are derived from both local 
synthesis and uptake from the blood (Rapoport et al., 2001). Once taken up by the 
BBB, neurons have fatty acid (FA) transporters. They also express enzymes for de 
novo lipid synthesis (Le Foll et al., 2009). However, astrocytes are the only brain 
cells able to oxidize FA, such as palmitate (further discussed in the chapter regarding 
astrocytes), whereas other FAs such as arachidonate, are mainly incorporated into 
phospholipids (Rapoport et al., 2001). 
Cumulative evidence suggests that hypothalamic FA sensing regulates energy 
expenditure, insulin secretion and action, hepatic glucose production (HGP), and 
food intake (Cruciani-Guglielmacci et al., 2004; Lam et al., 2005; Obici et al., 
2002a). For instance, prolonged intracerebroventricular (ICV) infusion of the long-
chain fatty acid oleic acid decreases food intake as well as HGP (Obici et al., 2002b). 
It has also been shown that central FA infusion decreases the sympathetic tone 
(Magnan et al., 1999), which could contribute to the FA-induced increase of glucose-
induced insulin secretion. 
However, the physiological significance of such findings after direct ICV 
infusion can be questioned, since infusions of FA in the systemic circulation or 
directly into the carotid arteries are more physiological stimuli. Studies from Barry 
Levin’s lab, using a microdialysis technique showed that after an 18-hour fast, high 
fat diet (HFD) leads to reduced caloric intake, with a delay of 3-6 hours. Moreover, 
by using hymeglusin, an inhibitor of astrocyte ketone production, they demonstrated 
that the effect was mediated through astrocyte ketone production, whereas the 
mechanism for this delayed effect on caloric intake was not addressed (Le Foll et al., 
2014). 
However, as discussed by the authors the concept that increases in brain FA 
levels acts as a satiety signal to inhibit feeding is contradictory to what one might 
expect since serum FFA are increased during fasting, a condition in which food 
intake should increase. Moreover, it is well established that early in the course of 
HFD, the hypothalamus becomes resistant to the adipostatic central actions of insulin 
and leptin (Prada et al., 2005). The induction of central leptin and insulin resistance 
has been suggested to be mediated through hypothalamic inflammation, and several 
potential mechanisms underlying hypothalamic inflammation in the context of HFD 
have been described (reviewed by (Velloso and Schwartz 2011)). 
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2.7 Astrocytes 
Astrocytes (from the Greek words άστρο=star and κύτταρο=cell) are the most 
abundant type of glial cells, accounting for approximately 50% of all the brain cells 
(Verkhratsky A 2013). Astrocytes, along with the endothelial cells of brain 
capillaries and pericytes, form the blood-brain barrier. Moreover, in case of an 
ongoing inflammatory process, astrocytes become activated and proliferate (a term 
known as astrogliosis), in order to create a physical barrier between the inflammation 
and neurons, and thus restrict damage.  
Because astrocytes are not electrically excitable, as neurons are, they have long 
been considered as only structural supporting cells for neurons. Against this until 
recently prevalent idea, astrocytes have received a lot of attention in recent years, 
and their importance in several aspects of not only energy homeostasis, but even 
evolution is currently under investigation. 
Recent studies support the concept that astrocytes may have played a significant role 
in the evolution of higher cognitive function. For instance, it has been shown that while 
the rat cerebral cortex contains approximately 0.4 glia to neuron cells, the human brain 
has a ratio of approximately 1.4 (Friede 1954; Pelvig et al., 2008). In line with this, it is 
reported that when Albert Einstein’s brain was examined the only difference that was 
found was that in the left cerebral area 39, Einstein’s brain had a significantly low 
neuronal:glia ratio, when compared to the controls (Diamond et al., 1985). It should be 
noted, however, that this example is just an interesting anecdotal finding rather than 
conclusive proof that an increased glial number contributes to better cognitive function. 
Regarding whole-body homeostasis there are several lines of evidence indicating 
direct and indirect control through astrocytes. First, hypothalamic astrocytes cooperate 
with specialized glucose sensitive neurons (Oomura et al., 1964) in detecting 
circulating glucose levels. This is suggested by studies showing that the expression of 
the insulin-independent glucose transporters GLUT1 and GLUT2 in astrocytes is 
critical for glucose sensing (Camandola 2018). Moreover, astrocytes are the only cell 
type in the brain able to utilize fatty acids either for oxidation (Edmond et al., 1987) or 
for the synthesis of ketone bodies (Edmond 1992). Furthermore, astrocytes express 
receptors for most of the hormones involved in energy homeostasis, including leptin 
(Diano et al. 1998), ghrelin (Fuente-Martin et al., 2016), IGF-1 (Garcia-Segura et al., 
2000), thyroid hormone (Dezonne et al., 2015), glucagon like peptide-1 (GLP-1) 
(Reiner et al., 2016), and insulin (Garcia-Caceres et al., 2016). 
Another interesting characteristic regarding astrocytes is that astrocytes in 
females and in males exhibit marked structural differences that could account, at 
least to some degree, for the gender specific differences in energy homeostasis. First, 
a female’s astrocytes have a simple bipolar structure compared to the complex 
stellate shape found in males (Mong et al., 1999). Second, they express receptors for 
estrogen, androgen and progesterone, which could explain the morphological 
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changes and possible different functional responses of hypothalamic astrocytes 
between males and females (Chowen et al., 2018; Garcia-Ovejero et al., 2005). Glial 
structural changes are seen in the hypothalamic areas both in rodents and in humans 
during the estrous cycle (Baroncini et al., 2010). It has also been shown that 
following HFD hypothalamic inflammation and astrogliosis is worse in male rodents 
than females. The combination of the above indicates that astrocytes are instrumental 
in regulating the responses of males and females to overfeeding.  
A. 
 
B. 
 
Figure 1.  Astrocytes are the energy hubs of the brain. They take up glucose and convert it to 
lactate through the astrocyte neuron lactate shuttle (ANLS). The fatty acids that are 
taken up by astrocytes can be oxidized, or used for ketone production. Brain glycogen 
is also exclusively found in astrocytes. A) Astrocytes (along with brain endothelium, and 
pericytes) form the BBB. B) Zoomed image of A) to show the metabolic pathways 
between astrocytes and neurons (Exemplified Figures). FAS: fatty-acid synthesis; 
ACoA: acetyl-CoA; AACoA: acetoacetyl-CoA; MCT: monocarboxylate transporters; 
FATP: fatty-acid transporter. 
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2.8 Central inflammation and astrogliosis in obesity 
Astrocytes are the most abundant glial cells of the CNS and are characterized by 
numerous cytoplasmic processes radiating from the glial cell body or soma. All 
astrocytic processes contain intermediate filaments of glial fibrillary acidic protein 
(GFAP), and antibodies against this protein provide a simple method to stain these 
cells. Astrocytes form part of the BBB and help regulate the entry of molecules and 
ions from blood into CNS tissue. Although the association between obesity and low-
grade systemic inflammation is well established in humans (Hotamisligil 2006), 
evidence of obesity-related cerebral inflammation in humans is still lacking. 
Preclinical studies have shown that overfeeding with HFD induces astrocyte 
proliferation in rats, a term known as astrogliosis (Thaler et al., 2012). Interestingly, 
hypothalamic inflammation develops within few days from the onset of HFD, before 
significant weight gain occurs, and it is concomitant with the onset of leptin 
resistance and upregulation of neuronal stress factors (Munzberg et al., 2004; Thaler 
et al., 2012). In line with this, it has been shown that genetically modified mouse 
models with decreased inflammatory signaling (mice deficient in the toll-like 
receptor adaptor molecule MyD88), were protected from the HFD-induced weight 
gain and from the development of leptin resistance (Kleinridders et al., 2009) 
Furthermore, Thaler and colleagues provided evidence of astrogliosis in human 
obesity by showing a positive association between BMI and the hyperintensity of the 
mediobasal hypothalamus (MBH) compared to the amygdala assessed by MRI 
(Thaler et al., 2012). This finding was later confirmed also by applying a quantitative 
MRI technique to measure relaxation time in the MBH, with both obesity and insulin 
resistance being associated with higher MBH intensity and, therefore hypothalamic 
gliosis (Schur et al., 2015). 
It has also been recently shown that the signal from [18F]FDG-PET in the brain 
is more likely driven by astrocytes and not by neurons as originally thought (Zimmer 
et al., 2017). Thus, central inflammation and astrogliosis could offer a plausible 
explanation for the increased insulin-stimulated brain glucose uptake in obese and 
insulin resistant subjects seen consistently in our previous studies (Hirvonen et al., 
2011; Tuulari et al., 2013). This hypothesis is currently under investigation by our 
group, but is not included in the present thesis.  
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2.9 Methods to measure brain substrate 
metabolism in humans 
2.9.1 Arteriovenous difference technique 
Arteriovenous difference (AV) technique is based on the concentration difference of 
a metabolite between an artery delivering the tissue of interest and a vein leaving 
from the tissue (Zierler 1961). By applying this method Owen and colleagues have 
shown that during fasting the brain extracts glucose and ketone bodies (Owen et al., 
1967). A subsequent study showed that, in the postabsorptive state, during 
euglycemic hyperinsulinemia, as well as during hypoglycemia, glucose is the main 
substrate for oxidation in the brain. Moreover, in the first two conditions 
(postabsorptive state and euglycemic hyperinsulinemia), glucose uptake could 
account for practically the entire oxygen consumption. During acute hypoglycemia, 
glucose could account for approximately 90-92% of oxygen consumption, indicating 
that other substrates are also used (even though still in small amounts) by the brain 
(Wahren et al., 1999). As this technique is highly invasive, its use has been limited 
in recent years.  
2.9.2  Magnetic resonance spectroscopy 
With magnetic resonance spectroscopy (MRS), also known as nuclear magnetic 
resonance (NMR) it is possible to measure concentrations of various metabolites 
inside the tissue of interest. Thus, compared to AV differences technique and 
positron emission tomography, MRS has the advantage of not being invasive and not 
exposing the participants to ionizing radiation. Regarding the physics of MRS, MRS 
is feasible “on any nucleus possessing a magnetic moment” (de Graaf 2018). The 
most commonly used nuclei with this property are proton (1H), carbon-13 (13C), 
phosphorus (31P) and sodium (23Na). Even though the number of relevant nuclei is 
limited, MRS provides the unique possibility to study simultaneously several 
metabolites. Thus, 1H MRS, using the proton nucleus, which is the most sensitive 
nucleus for MRS, allows the detection of a number of important neurotransmitters, 
such as glutamate and GABA, other metabolites, such as N-acetyl-aspartate, 
creatine, glutamine, and choline as well as glucose and lactate.  
With 13C MRS it is possible to study the fluxes through important metabolic 
pathways, like the Krebs cycle. Also glycogen deposits can be studied with 13C MRS. 
31P MRS provides information about energetically important metabolites, such as 
ATP, intracellular pH, and reaction fluxes (de Graaf 2018). 
The application of MRS techniques in the clinic is potentially interesting. 
However, MRS is challenging for several reasons. First and foremost, because of the 
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magnitude of water resonance (which is much larger than the concentration of the 
metabolites), the detection of metabolites of interest can be difficult. Secondly, other 
large signals such as extracranial lipids, can also interfere with small metabolite 
signals. Thirdly, heterogeneous magnetic field distributions significantly decrease 
the spectral resolution (de Graaf 2018).  
 
Figure 2. A typical 1H NMR spectrum acquired from an obese volunteer (source: BARIBRAIN 
study). The green line shows the glucose peak. The red line shows the ‘’raw’’ acquired 
spectrum. 
2.9.3 Positron emission tomography 
Positron emission tomography (PET) is a medical imaging technique, which utilizes 
short half-lived radionuclides incorporated into biological molecules, in order to 
image molecular processes. Nowadays PET is considered the gold standard 
technique for measuring substrate turnover in humans in vivo. The positron emitting 
radionuclides are produced with a cyclotron. The most common way of 
administrating a radiotracer is intravenously, but also other modes of administration 
can be used; for instance, the inhalation of gaseous tracers like marked oxygen 
[15O]O2 and marked carbon dioxide [15O]CO2 (Turku and Oikonen 2019). The tracers 
are usually administered in bolus by the researcher in charge, but in case of very 
short-lived tracers (like radiowater), automated systems are used for the 
administration of the tracer. A PET scanner detects the radioactivity of the tracer that 
accumulates in the tissues of interest. The acquired data are then transformed into an 
image, which is analyzed using adequate modeling. Depending on the tracer used 
and the modeling that will be applied for the analysis of the data, blood samples 
Review of the Literature 
 25 
(arterial or “arterialized” venous) are taken for measuring radioactivity in plasma 
and the proportion of metabolites.  
 
Figure 3.  The study volunteer is lying inside the PET/CT scanner (GE Discovery,”Sampo”), with 
only the covered legs in view. The researcher is performing a euglycemic clamp in 
combination with PET scanning. Depending on the organ/tissues studied the volunteer 
enters a specific depth inside the PET camera. Notice also the two infusion lines for 
glucose and insulin. Rhythm of ECG is also monitored during the whole length of the 
study. Photo taken by Sanna Himanen. In the PET Centre, it is common to name the 
PET scanners based on names from the Finnish early 19th-century national epic story 
of Kalevala. Other names for PET scanners currently in use are “Aino”’ and “Ilmari”’. 
2.10 Physical principles of the PET  
By definition, PET tracers emit positrons, and thus the tracer undergoes nuclear 
decay continuously. The emitted positrons collide with electrons and, as a result, are 
annihilated. The process of annihilation converts the mass of these colliding particles 
into energy and consequently two gamma (γ) photons of equal energy are emitted in 
opposite directions. The emitted gamma photons are detected by the PET scanner. 
The obtained raw data is processed by computers to form a reconstructed 
tomographic image.  
Most of the photons are however lost because of their absorption into the body, the 
amount depending on the size of the body in the field of view. 
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This loss of detection is called attenuation. Attenuation varies depending on the 
studied organ (for instance attenuation is low in the lungs, and high in dense tissues 
such as bones) (Turku and Oikonen 2019). Attenuation leads to severe artefacts in 
the PET image, and attenuation correction is warranted during image reconstruction. 
This is the main reason why low resolution CT images are also acquired (for the 
attenuation correction) when PET studies are performed.  
 
Figure 4. Drawing depicting the principles of PET; Modified from van der Veldt et al., 2013. 
The two tracers that have been used in this thesis are [18F]FDG and 14(R,S)-
[18F]fluoro-6-thia-heptadecanoic acid [18F]FTHA.  
2.11 Limitations of PET Imaging 
Administration of a PET tracer causes exposure to ionizing radiation for the studied 
subject. For this reason, the number of studies that can be performed on one study 
volunteer is limited. For instance, a typical dose for brain (and rest of the body) 
during [18F]FDG imaging of 180 MBq of [18F]FDG corresponds to an effective dose 
of 3.5 mSv, whereas the mean annual background radiation dose in Finland is 3.2 
mSv. The radiation from computerized tomography, taken for the attenuation 
correction should also be added to this amount of ionizing radiation burden. The 
effects of such a dose on the subject’s health are marginal. However, there are ethical 
guidelines, which set the maximum acceptable radiation burden for healthy 
individuals in order to ensure safety. Typically this radiation limit is around 10 mSv. 
PET imaging cannot investigate more than one function at a time. Thus, if the 
[18F]FDG tracer is given, only glucose uptake can be evaluated, whereas if 
[18F]FTHA is given, free-fatty acid uptake can be addressed. In case more than one 
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function is to be studied (for instance both perfusion and glucose uptake), the 
necessary time for complete decay of the first tracer needs to have passed before 
administering the second tracer. This can make PET studies especially time-
consuming. The field of view of the PET scanner also limits the ability to study 
several organs. Furthermore, the resolution of the (current) PET scanners is about 
3.5 mm, which limits the possibility to study very small brain areas, such as the 
hypothalamus.  
2.12 Bariatric surgery as a treatment for morbid 
obesity 
Diet modification, and lifestyle intervention have proved to be only a weak arm in 
the battle against obesity. Even though considerable weight loss can be achieved 
with lifestyle interventions (up to 20% of initial body weight) (Weiss et al., 2007), 
when the lifestyle intervention is stopped, weight regain typically occurs. Moreover, 
some studies have shown that the higher the weight loss during the lifestyle 
intervention, the higher the weight regain once the intervention is ceased (Weiss et 
al., 2007). Weight regain can be detrimental since weight cycling may have adverse 
health effects (Vergnaud et al., 2008), and even lead to increased all-cause mortality 
and mortality from coronary disease (Brownell and Rodin 1994). In contrast, 
bariatric surgery (BS) is the most powerful weapon in the battle against morbid 
obesity. Apart from inducing rapid weight loss, it is also very effective in 
maintaining weight loss, with an average of 32 kg weight reduction at five years after 
intervention (Puzziferri et al., 2014). 
Before surgery, candidates for BS, undergo thorough screening to exclude 
primary causes of obesity and other disorders which could jeopardize the weight loss 
achieved after bariatric surgery, or even risk the patients’ health. Subjects also 
receive nutritional counseling by a dedicated nutritionist. Before surgery, subjects 
undergo a very-low calorie diet, during which they must lose weight. Weight loss 
prior to surgery is a fundamental prerequisite and is also an additional safety 
measure, since it helps in the surgical procedure. Even though several bariatric 
surgery types have been described the most successful ones worldwide are: 1) Roux-
en-y gastric bypass, which is a combination of restrictive and malabsorptive 
intervention and 2) Sleeve gastrectomy (usually performed laparoscopically, so the 
abbreviation commonly used is LSG), which is purely restrictive.  
Although BS has numerous beneficial effects, including remission of T2D, it can 
also have serious and life-threatening adverse effects. Among these, postprandial 
hypoglycemia (PPHG) is a common, but often under-diagnosed complication of both 
RYGB and LSG (Seaquist et al., 2013). Also, some degree of weight regain typically 
occurs one to two years after surgery, and it has been recently shown that subjects 
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suffering from postprandial hypoglycemia lose less weight compared to those who 
do not develop post prandial hypoglycemia (Rebelos et al., 2020a). Subjects who 
have undergone RYGB or other malabsorptive treatments (for instance 
biliopancreatic diversion) also risk vitamin, and ferrum deficiencies and thus, long 
(even lifelong) follow-up is needed. All in all, BS is today the most powerful method 
to achieve weight loss and improvement of the glucometabolic status in subjects 
affected by morbid obesity. However, it is also a treatment that follows the subject 
for his/her whole life-time, so special attention need to be paid to the selection of 
good candidates for undergoing BS. Additionally, frequent medical controls are 
warranted in order to achieve the best outcomes and minimize adverse events related 
to BS.  
For the aims of the studies enclosed in this thesis, which focused on the effects 
of obesity and weight loss, BS provides an excellent interventional approach.
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3 Aims 
This thesis set out to investigate whether the brain (through brain substrate handling) 
is involved in the control of whole-body homeostasis and whether an increased brain 
substrate uptake predicts any metabolic outcome at follow-up.  
 
The specific objectives of this thesis are: 
I. To evaluate whether brain glucose uptake correlates with endogenous glucose 
production in morbidly obese and lean subjects and whether bariatric surgery 
affects such potential association. 
II. To evaluate whether brain substrate utilization correlates with the parameters 
of beta cell function assessed with oral glucose tolerance modeling. 
III. To evaluate whether brain fatty acid uptake is higher in morbidly obese than 
lean women and whether brain fatty acid uptake is decreased following 
bariatric surgery. 
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4 Materials and Methods 
4.1 Study subjects 
This thesis includes data from a total of 124 subjects, who each participated in one 
of the three studies presented. All study participants were Caucasian. None of the 
study subjects had any clinical diagnoses of neurological diseases or severe 
psychiatric disorders. All subjects underwent a screening visit before inclusion in the 
study. Prior to inclusion, each participant gave written informed consent. Each study 
protocol included in this study was approved by the Ethics Committee of the Hospital 
District of Southwest Finland and conducted in accordance with the Declaration of 
Helsinki. 
Study I included 20 morbidly obese subjects eligible for BS and 14 lean controls. 
Of the 20 obese subjects, 17 returned for the post-bariatric surgery studies. In study 
II cross-sectional data of 120 subjects were included. Study III consisted of 24 
morbidly obese subjects and 14 lean individuals. 21 obese subjects were re-studied 
after BS. Of note, the study participants in study I and III were included in the cross-
sectional dataset of study II.  
Inclusion criteria for the patient population 
1) BMI > 40 kg/m2 or > 35 if there is an additional risk factor (for instance 
T2D, sleep apnea) 
2) Age: 18-60 years 
3) Previous, carefully planned, conservative treatments for obesity have 
failed 
Exclusion criteria for the patient population 
1) BMI > 60 kg/m2 
2) Weight more than 170 kg 
3) Waist circumference > 150 cm 
4) Mental disorders or poor compliance 
5) Eating disorders (e.g. binge eating) or excessive consumption of alcohol 
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6) Active peptic ulcer disease 
7) T2D requiring insulin treatment or fasting glucose more than 7 mmol/l 
Inclusion criteria for the control group 
1) BMI 18-27 kg/m2 
2) Age 18-60 years 
3) Fasting plasma glucose < 6.1 mmol/l 
4) Normal glucose tolerance test (studied with OGTT) 
Exclusion criteria for healthy participants 
1) Blood pressure > 140/90 mmHg 
2) Mental disorder or poor compliance 
3) Any chronic medical defect or injury which hinders/interferes with 
everyday life 
4) Eating disorder or excessive use of alcohol 
Exclusion criteria for both groups 
1) Pregnancy 
2) Past participation in nuclear medicine imaging studies 
3) Any other condition that in the opinion of the investigator could create a 
hazard to subject safety, endanger the study procedures, or interfere with 
the interpretation of study results 
4) Presence of any ferromagnetic objects that would make magnetic 
resonance imaging contraindicated 
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Table 1.    Characteristics of the study participants*. 
Scanning 
conditions 
Euglycemic 
clamp and 
Fasting 
Euglycemic 
clamp and 
Fasting 
Fasting 
* In Study II (a): 67 subjects studied with [18F]FDG under euglycemic hyperinsulinemic clamp; (b): 34 women studied with [18F]FTHA under 
fasting conditions; and (c): 45 subjects studied with [18F]FDG during fasting. 
 
PET tracer(s) 
[18F] FDG 
[18F] FDG 
[18F]FTHA 
[18F]FTHA 
BMI 
(kg.m-2) 
37 ± 10 
32 ± 9, 
34 ± 10, 
34 ± 10 
34 ± 10 
Sex 
(M/F) 
5/29 
13/54, 
0/34, 
10/35 
 
(0/38) 
Age 
(years) 
47 ± 8 
46 ± 9, 
45 ± 9, 
43 ± 11 
43 ± 11 
Number of 
subjects 
20 obese 
and 14 lean 
67 study (a), 
34 study (b), 
45 study (c) 
24 obese 
and 14 lean 
Characteristics 
Obese before and after 
BS and lean controls 
Cross-sectional data of 
all subjects who had β-
cell function data and 
PET 
Obese before and after 
BS and lean controls 
Study 
I 
II 
III 
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4.2 PET-studies (I-III) 
Insulin clamp [18F]FDG studies (I, II): The euglycemic hyperinsulinemic clamp 
was performed as previously described (DeFronzo et al. 1979). In brief, after an 
overnight fast, the subjects were given a primed-continuous infusion (40 mU.m-
2.min-1) of insulin (Actrapid; Novo Nordisk, Copenhagen, Denmark). During the 
clamp, a variable rate of a 20% glucose solution was infused in order to maintain 
euglycemia (5 mmol/L). Plasma glucose levels were measured every 5‒10 minutes 
throughout the study. Approximately 100±10 minutes into the clamp, [18F]FDG 
(187±9 MBq) was injected intravenously over a 15 second period and brain 
[18F]FDG radioactivity was measured either immediately thereafter for 40 minutes 
(dynamic scan) or after 70‒80 minutes (static scan for 10 minutes). For this reason, 
when studies were pooled and re-analyzed (as in study II) the time interval between 
the [18F]FDG injection and the brain scan was also used as a covariate in the 
statistical analysis. During the clamp, plasma glucose, plasma insulin and serum FFA 
were taken at baseline and every 5, 30 and 60 minutes respectively. The M-value 
(the index of insulin sensitivity, from “Metabolised glucose”) was calculated by 
using three 20 minutes time intervals, between 60 and 120 minutes into the clamp. 
Fasting [18F]FDG studies (I, II): During fasting, an intravenous bolus (188±7 MBq) 
of [18F]FDG was given, following which the dynamic PET imaging of the brain 
started and continued for 40 minutes. Blood samples were drawn periodically during 
the entire scanning period to measure radioactivity levels. 
[18F]FTHA studies (II, III): Following an overnight (10‒12 h) fast, an 
intravenous bolus (185±46 MBq) of [18F]FTHA was given, following which the 
dynamic PET imaging of the brain started and continued for 40 minutes. Blood 
samples were drawn during the entire scanning period to measure FFA as well as 
radioactivity levels and metabolites. 
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Figure 5. Diagram of the experimental protocol of the [18F]FDG-PET studies during euglycemic 
hyperinsulinemic clamp (A, B) and fasting (C). The difference between studies (A) and 
(B) is that in (A) brain radioactivity is acquired immediately after [18F]FDG injection and 
lasts for 40 minutes, whereas in (B) brain radioactivity is acquired at the end and lasts 
for only 10 minutes. 
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Figure 6.  Diagram of the experimental protocol of the [18F]FTHA-PET. Studies were performed in 
the postabsorptive state. Note that the fasting [18F]FDG-PET and [18F]FTHA-PET 
protocols are identical. Brain radioactivity was acquired immediately after [18F]FTHA 
injection, and lasted for 40 minutes. 
4.3 Production and characteristics of radiotracers 
(I-III) 
The glucose analogue [18F]FDG (T1/2 =110 min) was produced with an automatic 
apparatus by a modified Hamacher method (Hamacher et al., 1986). After entering 
the cells, [18F]FDG is phosphorylized and remains trapped in tissue in proportion to 
its phosphorylation rate. 
The palmitate analogue [18F]FTHA (T1/2 =110 min) was synthesized by labelling 
14(R,S)tosyloxy6-thia-heptadecanoic acid with [18F]fluoride and with high-
performance liquid chromatography (Takala et al., 2002). After entering the cell, 
[18F]FTHA goes through partial mitochondrial β-oxidation, and remains trapped 
(Iozzo et al. 2003). In contrast to the other palmitate analogue available (11C-
palmitate), [18F]FTHA shows total fatty acid uptake, whereas 11C-palmitate 
undergoes rapid β-oxidation and the remaining radioactivity represents the non-
oxidized part (Karmi et al., 2010).  
The information regarding the fate of [18F]FDG and [18F]FTHA after entering the 
cells is exemplified and presented in Figure 7. 
 
Figure 7.  Exemplified cartoon depicting what happens when [18F]FDG and [18F]FTHA enter the 
cells.  
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4.4 PET scanners, PET image acquisition and data 
processing 
The studies were performed using either the GE Advance PET camera (General 
Electric Medical Systems, Milwaukee, WI), GE Discovery STE (General Electric 
Medical Systems, Milwaukee, WI, USA), or ECAT931/08 (Siemens Molecular 
Imaging, Inc., Knoxville, TN, USA). The scanners were cross-calibrated against the 
same VDC-404 Dose calibrator (COMECER Netherlands, Joure, the Netherlands). 
All data were decay- and attenuation- corrected, and reconstructed using a Hann 
filter with a cut-off frequency of 0.5 and a median root prior to reconstruction method 
3. Blood samples from an “arterialized” vein were drawn during the study and 
analyzed for radioactivity concentration in plasma using an automatic γ counter 
(Wizard 1480, Wallac, Turku, Finland), and measurement of radioactive metabolites 
(applicable for [18F]FTHA studies) .  
All studies were pre-processed similarly via the internally developed pipeline 
named MAGIA (http://emotion.utu.fi/softwaredata/) (Karjalainen et al. 2020). 
Dynamic PET images were motion corrected and mean images were calculated. 
Mean PET images were spatially normalized to the [18F]FDG template in Montreal 
Neurological Institute (MNI) space (MNI International Consortium for Brain 
Mapping) using SPM12 (www.fil.ion.ucl.ac.uk/spm/) running on Matlab for Linux 
(version 9.1.0; Math Works, Natick, MA). Normalization parameters were 
subsequently applied to corresponding dynamic images and Ki (influx constant rate) 
parametric images were calculated. Parametric images were smoothed at 8 mm full-
width at half-maximum. 
A global and eight other brain regions of interest (CER-A, anterior cerebellum; 
CER-P, posterior cerebellum; FRO, frontal lobe; LIMB, limbic lobe; MID, midbrain; 
OCC, occipital lobe; PAR, parietal lobe; TEMP, temporal lobe) were selected via 
wfu pickatlas (www.fmri.wfubmc.edu/cms/software) and extracted from the 
parametric images via Marsbar (in order to perform the linear regressions with the 
various predictors). 
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4.5 PET imaging 
 
Figure 8. Raw [18F]FDG-PET and [18F]FTHA-PET mean images presented on the same scale, to 
show visually to the reader the obvious differences in brain glucose uptake and brain 
fatty acid uptake. Even though the brains of different subjects are illustrated, subjects 
were matched for sex (women), age (42 years), and BMI (40 kg.m-2). 
4.5.1 PET Quantification: semiquantitative and quantitative 
approaches 
There are several approaches to presenting PET data. Generally, these are divided 
into the semiquantitative and quantitative approaches.  
Standardized uptake value (SUV) is a semiquantitative method for assessing 
tissue metabolic uptakes, which are calculated by dividing tissue radioactivity 
concentration by injected dose and multiplied by body weight (SUV=radioactivity 
concentration/(dose/body weight)) (Turku and Oikonen 2019). In principle, SUV is 
based on the fact that the administered dose divided by the subject’s body weight 
represents the mean radioactivity concentration in the whole body, and that the 
average SUV in one person (whole body) is 1 g/ml. For example, if there is 
increased/decreased uptake in some tissue (for instance, adipose tissue), it will affect 
the SUV in the region of interest (for instance, brain), even though this is not due to 
the characteristics of the tissue of interest, but rather, it depends on the availability 
of the tracer. Accuracy of SUV is inferior to the quantitative three-compartment 
modeling, Patlak plot and fractional uptake rate (FUR), which account for the 
(variability of the) availability of the tracer in arterial plasma. 
For quantitative approaches blood sampling (or acquisition of aorta images 
within the field of view) is mandatory in order to account for the input curve. Full 
compartmental model is the gold standard for quantitative PET analysis. It requires 
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radioactivity acquisition from the start of the study (injection of the tracer), and 
frequent sampling. Full compartmental model is however usually not used because 
both graphical analysis (Gjedde-Patlak plot) and FUR represent reliable 
alternatives.  
In the Gjedde-Patlak plot, plasma input data must be collected from the 
injection of the tracer. Tissue (of interest) data can be either acquired either 
immediately after injection of the tracer or later. Typically, when tissue data are 
acquired immediately after injection, the first 15-20 minutes are excluded from the 
analysis, in order to obtain a stabilization period of the tracer in the examined 
tissue. This discarding of the first minutes of the tissue data, is mandatory so that 
when the Gjedde-Patlak plot is applied, equilibrium of the tracer (in the 
extracellular and intracellular compartments) of the tissues is achieved, and thus 
the plot becomes linear. This is better explained in the Figures that follow. Figure 
9A1 shows the plasma and tissue curves of [18F]FDG from injection until 40 
minutes of scanning. The time frame from 20 minutes until the end of the scan is 
selected to be analysed. When applying the Gjedde-Patlak plot (Figure 9A2) a line 
is created, where at the y axis there is tissue concentration/plasma concentration, 
and at the x axis there is the area under the curve (AUC) of tissue 
concentration/plasma concentration. The slope of the line represents the influx 
constant (Ki) which is then multiplied by the circulating substrate levels (for 
[18F]FDG, with plasma glucose), and this value represents the tissue glucose 
uptake. In case of [18F]FDG a lumped constant correction is also applied to account 
for the difference between glucose and [18F]FDG uptake from the studied tissue.  
Also, whereas FUR tissue data can be acquired immediately after injection, or in 
a later phase, plasma input data must be available from injection. When FUR is 
applied the radioactivity value of the middle of the selected frame used is divided by 
the integral of plasma input curve from the beginning until the same time point that 
was used for the tissue radioactivity (Figure 9B). Then, the same procedure as 
described above for the Gjedde-Patlak plot is performed in order to obtain glucose 
(or fatty acid) uptake values. 
Results from Gjedde-Patlak plot and FUR analysis show excellent correlation. 
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A1.  
 
A2. 
 
B. 
 
Figure 9. A1 and 9A2 figures showing the principle of the Gjedde-Patlak plot. First, the time range 
is selected (in this case from 20 min to the end of the brain scan). Blue line shows 
plasma input curve, and purple line shows the brain tissue activity curve. Then, when 
the Patlak plot is applied, the model gives the volume of distribution (Vd) that is the point 
where the modelled tissue curve crosses the Y axis (intercept). The slope of this line 
(showed in yellow), gives the Ki. Glucose uptake can then be calculated as Ki multiplied 
by the average plasma glucose levels from the injection of [18F]FDG to the middle of the 
scan, and divided by the lumped constant ( GU= Ki*PG/LC). B figure showing how 
glucose uptake can be calculated with FUR calculation. FUR =tissue radioactivity at the 
selected time point (in this case the middle point of the frame from 30-40 min) divided 
by the integral of plasma input curve from the beginning until the same time point that 
was used for the tissue radioactivity. To obtain GU values FUR is then multiplied by the 
average plasma glucose levels from the injection of [18F]FDG to the middle of the scan. 
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4.5.2 Modeling 
In study (I), brain glucose uptake was quantified from [18F]FDG by using graphical 
analysis to calculate the influx constant rate of tracer uptake (Ki) (Patlak and 
Blasberg 1985). The input function for graphical analysis was derived from 
arterialized blood samples. The rate of glucose uptake (micromoles per gram per 
minute) was calculated by multiplying Ki by the plasma glucose concentration (from 
[18F]FDG injection to the end of the brain scan) and dividing this by the lumped 
constant of the brain, and the brain density (1.04 g/ml).  
In study (II), a different approach was used since studies where brain 
radioactivities were acquired at different time points were pooled together. Brain 
glucose uptake was quantified using FUR. This variation was needed because, for 
early studies graphical analysis, and FUR were possible options, but for the late 
studies (since brain radioactivity was static at the late studies), the slope of the line 
could not be determined and as such, FUR was preferable.  
For all [18F]FDG-PET studies the lumped constant value for the brain was set at 
0.65 (Wu et al. 2003).  
In studies (II, and III), fatty acid uptake was simply quantified using FUR as 
BFAU = FUR*(fatty acids).  
4.6 Endogenous glucose production (EGP) 
determination (I) 
EGP was calculated, as previously described, by Iozzo et al. (Iozzo et al. 2006). Of 
note, this method has been validated against the gold standard of D-[6,6-2H] glucose.  
In brief, EGP was calculated by subtracting the exogenous glucose infusion rate 
(GIR) from the rate of disappearance of glucose (Rd) during the euglycemic 
hyperinsulinemic clamp:  
EGP = R𝑑𝑑 + V𝑔𝑔lucose ×Δglucose/ΔT – GIR 
GIR is corrected by a space correction (DeFronzo et al. 1979) where Vglucose is the 
estimated glucose distribution volume (0.19 l/kg), Δglucose is the change in glucose 
from [18F]FDG injection to the end of sampling (mmol/l), and ΔT is the time between 
[18F]FDG injection and the end of sampling (min). 
Glucose disappearance rate (Rd) was calculated using [18F]FDG clearance 
corrected by tracer lost to urine (Iozzo et al. 2006) according to the following 
formula:  
R𝑑𝑑 =((dose[18F]FDG – urine[18F]FDG)/AUC[18F]FDG )∗ avgglucose 
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Where dose [18F]FDG is the activity of the injected [18F]FDG, urine [18F]FDG is 
[18F]FDG secreted to urine from the tracer injection until voiding bladder at the end 
of the study, AUC[18F]FDG is the area under the curve representing [18F]FDG from the 
tracer injection to infinity, and avgglucose is the average glycemia during the interval 
between the time of [18F]FDG injection and the end of sampling. 
4.7 Beta cell function (II) 
ß-cell function was assessed from OGTT modeling. This model describes the 
relationship between insulin secretion rate (ISR, expressed in pmol.min-1.m-2) and 
glucose concentration as the sum of two components (Mari et al., 2002a; Mari et al., 
2002b). The first component represents the dependence of ISR on glucose 
concentration through a dose-response function relating the two variables. From the 
dose-response, ß-cell glucose sensitivity (the slope) is calculated. The dose-response 
is modulated by a potentiation factor, accounting for various mechanisms 
(antecedent hyperglycemia, non-glucose substrates, gastro-intestinal hormones, 
neural modulation). The potentiation factor averages 1 during the test and expresses 
relative potentiation or inhibition of ISR; its excursion is quantified by the ratio 
between the two-hour and the baseline value (potentiation). The second ISR 
component represents the dependence of ISR on the rate of change of glucose 
concentration and is determined by a single parameter (rate sensitivity), which is 
related to early insulin release (Mari and Ferrannini 2008). The model parameters 
were estimated from glucose and C-peptide concentrations (using C-peptide 
deconvolution) (Van Cauter et al., 1992) as previously described (Mari et al., 2002b). 
4.8 Insulin clearance 
Insulin clearance was calculated from the OGTT as mean insulin secretion divided 
by mean insulin concentration (Camastra et al., 2005). 
4.9 Blood measurements 
Plasma glucose was measured in the laboratory of the Turku PET Centre in duplicate 
using the glucose oxidase technique (Analox GM7 or GM9, Analox Instruments 
Ltd., London, UK). Glycosylated hemoglobin (HbA1c) was measured with ion-
exchange high performance liquid chromatography (Variant II Haemoglobin A1c, 
Bio-Rad Laboratories, CA, USA). Plasma insulin was determined by time-resolved 
immunofluorometric assay (AutoDELFIA, Perkin Elmer Life and Analytical 
Sciences). C-peptide was measured with electrochemiluminescence analyzer 
immunoassay (ECLIA) (Roche Diagnostics GmbH, Mannheim, Germany). Serum 
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FFA were measured with a photometric enzymatic assay (FFA-HR(2). Wako 
Chemicals GmbH, Neuss, Germany) on Modular P800 automatic analyzer (Roche 
Diagnostics, Mannheim, Germany). Serum high-sensitivity C-reactive protein (hs-
CRP) was analyzed with the sandwich immunoassay method using an Innotrac Aio1 
immunoanalyzer (Innotrac Diagnostics, Turku Finland). Serum adipokines were 
analyzed in duplicate by using Milliplex Human Serum Adipokine (Panel A) kit 
[cat.no HADK1-61K-A] containing interleukin-6 (IL-6), interleukin-8 (IL-8), tumor 
necrosis factor alpha (TNFα), and leptin. 
4.10 Metabolomic measurements (I) 
Metabolic biomarkers were quantified from the serum using high-throughput proton 
NMR metabolomics (Nightingale Health Ltd, Helsinki, Finland; University of 
Eastern Finland, Kuopio, Finland). This method provides simultaneous 
quantification of routine lipids, fatty acid composition, and various low-molecular 
metabolites including amino acids and, ketone bodies as well as lipoprotein subclass 
profiling with lipid concentrations within 14 subclasses. The 14 lipoprotein subclass 
sizes were defined as follows: extremely large VLDL with particle diameters from 
75 nm upwards, five VLDL subclasses (average particle diameters of 64.0 nm, 53.6 
nm, 44.5nm, 36.8 nm, and 31.3 nm), IDL (28.6 nm), three LDL subclasses (25.5 nm, 
23.0 nm, and 18.7 nm), and four HDL subclasses (14.3 nm, 12.1 nm, 10.9 nm, and 
8.7 nm). The following components of the lipoprotein subclasses were quantified: 
phospholipids, triglycerides, cholesterol, free cholesterol, and cholesterol esters. The 
mean sizes of VLDL, LDL, and HDL particles were calculated by weighting the 
corresponding subclass diameters with their particle concentrations. Details of the 
experimentation and applications of the NMR metabolomics platform have been 
discussed previously (Inouye et al. 2010; Soininen et al. 2015).  
4.11 FLAIR MRI sequence to assess brain 
inflammation and variability of the method (III) 
To measure mediobasal hypothalamic (MBH) gliosis, the signal intensity (SI) was 
retrospectively measured from coronally oriented fluid-attenuated inversion 
recovery (FLAIR) images from magnetic resonance imaging (MRI), as previously 
described (Kreutzer et al., 2017; Schur et al., 2015; Thaler et al., 2012). FLAIR 
images were gathered as part of the study protocol on a Philips 1.5T MRI scanner 
(Philips Ingenuity), with the following image parameters: repetition time: 11000 ms, 
echo time: 140 ms, inversion time: 2800 ms, slice thickness 5 mm. Briefly, circular 
regions of interest (ROIs, about 4 mm2) were placed on one coronal slice onto MBH, 
which was identified as a bilateral most caudal brain region situated between the 
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optic chiasm anteriorly and the mamillary bodies posteriorly. The amygdala, visible 
on the same slice in the medial temporal lobe, was chosen as the reference region 
(ROI about 20 mm2) for the normalization of MBH SI, and the MBH-amygdala SI 
ratio served as the primary outcome measure of hypothalamic gliosis. To examine 
whether SI findings were specific to MBH, the putamen was used as an internal 
control region (ROI about 20 mm2), and putamen-amygdala ratios were calculated. 
All measurements were carried out by a board-certified staff neuroradiologist (J.H.). 
Thirty cases were also independently analyzed by a second neuroradiologist (M.N.), 
and between-rater reliability was assessed by determining the variability (absolute 
difference between measurements by two raters, divided by the average of those 
measurements), and by determining the intraclass correlation coefficients (ICC), 
where <0.5 is poor, 0.5-0.75 is moderate, 0.75-0.9 is good, and >0.9 is excellent 
reliability. We found low inter-rater variability (3.6%), suggesting low measurement 
error, and an ICC estimate of 0.63, suggesting moderate agreement. 
4.12 Indirect calorimetry (III) 
Energy expenditure was measured using indirect calorimetry (Deltatrac II; Datex-
Ohmeda). Whole-body energy expenditure, substrate utilization rates, and 
respiratory quotients were calculated as previously described (Weir 1949). 
4.13 Surgical procedure (I and III) 
All surgeries were performed by the same team at Turku University Hospital. In 
brief, for RYGB a small gastric pouch of approximately 20-40 ml was created by 
dividing the upper part of the stomach. The jejunum was anastomosed to the gastric 
pouch approximately 50-70 cm distal to the ligament of Treitz. The alimentary limb 
was measured at 150 cm and a side-to-side jejunojejunal anastomosis was created 
between the alimentary and biliopancreatic limbs. Afterwards, the jejunum was 
transected between the two anastomoses. For LSG, the great curvature and the 
fundus were resected, leaving a tubular shaped stomach. 
4.14 Statistical analysis 
Data are presented as mean ± SD (or median [interquartile range IQR] for non-
normally distributed variables). Statistical analysis at the voxel and cluster level was 
performed with statistical parametric mapping (SPM) (SPM12 toolbox for Matlab). 
Linear regressions were performed in SPM to evaluate correlations between BGU 
(and BFAU) and single regressors (EGP, insulin secretion rate, potentiation, ecc.) 
while controlling for confounding factors (in the SPM contrast, the controlling 
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variables were set to a value of 0). Between groups comparisons (obese vs. lean and 
obese before and after surgery) were performed in SPM with two-sample t-test and 
paired t-test, respectively. Brain glucose (and fatty acid) uptake values were 
extracted from the global ROI with Marsbar plug-in for Matlab and visualized with 
the single regressors using scatter-plot correlation coefficients (r). The statistical 
threshold in the SPM analysis was set at a cluster level and corrected with false 
discovery rate (FDR) with p < 0.05. Further statistical analyses were done using JMP 
version 13.0 (SAS Institute, Cary, NC, USA). A p value < 0.05 was considered 
statistically significant. 
Associations between BGU and circulating metabolites were tested using 
Spearman correlations (Study I). Statistical analysis was performed using an R 
computing environment (version 3.4) (R Core Team 2017). Heatmaps were created 
with the gplots package (Warnes et al. 2016).  
4.15 Ethics 
A written informed consent was obtained from all study subjects prior to inclusion 
in the studies. All studies were approved by the ethical review committee of the 
Hospital District of Southwest Finland and carried out according to the principles of 
the Declaration of Helsinki, GMP, and GCP guidelines. 
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5 Results 
5.1 Brain glucose uptake correlates positively with 
liver glucose production (I) 
As expected, obese subjects had higher plasma glucose concentration, lipid profiles, 
and inflammatory markers at baseline compared to the age-matched lean controls. 
The anthropometric and biochemical characteristics of the two groups are listed in 
Table 2.  
Table 2. Anthropometric and biochemical characteristics of the study participants. 
 Controls Obese  p value 
  Pre Post  
M/W 4/8 1/19 0/16 - 
NGT/IGT/T2D 9/3/0 4/10/6 13/2/1* <0.0001 
Age (years) 43 ± 11 46 ± 9 47 ± 9 0.4 
BMI (kg.m-2) 23.2 [3.0] 43.1 [2.5] 32.2 [3.1]* # <0.0001 
FM (%) 32.4 [9.1] 48.1 [1.7] 41.9 [3.0]* # <0.0001 
Fasting plasma glucose (mmol.L-1) 5.5 ± 0.4 6.2 ± 0.8 5.4 ± 0.5* 0.01 
Insulin Clearance (L.min-1.m-2) 1.5 ± 0.3 1.1 ± 0.3 1.3 ± 0.3* 0.004 
HbA1c (%) 5.6 ± 0.3 5.8 ± 0.5 5.5 ± 0.3* 0.08 
Leptin (ng.mL-1) 15.5 [14] 55.7 [23] 26.9 [15]* # 0.0002 
IL-6 (pg.mL-1) 1.1 [1.2] 2.6 [2.0] 1.9 [0.6]* 0.02 
CRP (mg.L-1) 0.8 [1.3] 3.2 [5.1] 1.0 [1.8]* 0.003 
Total Cholesterol (mmol.L-1) 5.1 ± 0.8 4.4 ± 0.8 4.2 ± 0.5# 0.04 
HDL Cholesterol (mmol.L-1) 1.9 ± 0.5 1.3 ± 0.2 1.5 ± 0.2* 0.003 
LDL Cholesterol (mmol.L-1) 3.0 ± 0.7 2.8 ± 0.7 2.5 ± 0.5 0.5 
Triglycerides (mmol.L-1) 0.9 ± 0.4 1.3 ± 0.4 0.9 ± 0.2* 0.006 
ALT (U.L-1) 17 ± 7 31 ± 12 19 ± 10* 0.0007 
gGT (U.L-1) 15 [13] 30 [18] 13 [8] 0.0006 
Steady-state insulin (pmol.L-1) 392 ± 94 518 ± 190 467 ± 76# 0.04 
Steady-state glucose (mmol.L-1) 5.1 [0.2] 5.0 [0.1] 5.2 [0.1] 0.4 
M-value (µmol.kgFFM-1.min-1) 67.3 [43.3] 25.2 [23.0] 52.1 [34.0]*# <0.0001 
Fasting EGP (µmol.kgFFM-1.min-1) 15.49 [2.78] 14.82 [4.68] 14.76 [3.25] 0.8 
Fasting EGP (µmol.min-1) 724 [142] 899 [311] 754 [236]* 0.0004 
EGP clamp (µmol.kgFFM-1.min-1) 0.27 [7.74] 6.20 [8.18] 3.6 [5.56] 0.03 
EGP clamp (µmol.min-1) 12 [351] 390 [522] 208 [318] 0.006 
entries are mean ± SD or median [interquartile range]; p value for the comparison obese pre vs. 
lean controls; * = p value < 0.05 for the comparison obese pre vs. obese post; #= p value < 0.05 for 
the comparison obese post vs. lean controls. 
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In the post absorptive state, BGU was not different between obese and lean subjects, 
and EGP was higher in the obese than the lean subjects. During the clamp, plasma 
glucose levels were well-matched between the two groups. Even though the 
exogenous insulin infusion was adjusted for body surface area, steady-state serum 
insulin levels were higher in the obese due to lower insulin clearance in this group. 
As expected, obese subjects also had lower M-value and higher insulin-suppressed 
EGP; the two parameters were reciprocally related (Figure 10). 
 
Figure 10. Plasma glucose levels were well-matched between the two study groups (A), but insulin 
levels were higher at some time-points in the obese group (indicated with *) (B). 
Compared to lean subjects, the obese subjects had lower M-value (C) and higher EGP 
(D), with the two measurements being reciprocally related (E). 
Cross-sectionally, BGU during the clamp was higher in the obese compared to 
controls and correlated positively with insulin-suppressed EGP (r=0.51, p=0.003) 
(Figure 11). This association was driven by the obese group (r=0.60, p=0.006 in 
obese subjects, r=-0.1, p=0.7 in lean subjects). This association remained significant 
after accounting for BMI (r=0.66, p=0.009) or steady-state insulin (r=0.54, 
p=0.003). On the contrary, in the fasting state, BGU and EGP did not correlate. 
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Figure 11. A: SPM two-sample t-test between obese subjects pre-operatively and controls. Marked 
brain areas show regions with significantly higher BGU in the obese subjects than 
controls. Higher t-values denote larger differences between the groups. P values < 0.05 
cluster level, FDR corrected. D: corresponding boxplots showing the differences in BGU 
between the two groups. Data are mean ± SEM; * = p<0.05. B: SPM images of the 
association between BGU during clamp and insulin-suppressed EGP in the obese 
subjects pre-operatively. P values < 0.05 cluster level, FDR corrected. C: No association 
between BGU during clamp and EGP in lean controls. For images B and C marked brain 
areas show where the association between BGU and EGP was statistically significant. 
Higher t-values denote stronger association between BGU and EGP (color bar at the 
bottom). E, F: Corresponding scatterplots of the association between BGU and EGP in 
the obese and lean, respectively. 
In 26 subjects (19 obese and 7 lean) who had IL-6 and CRP measurements taken, the 
measurements were positively associated with BGU (r=0.52, p=0.006 at the cluster 
level for IL-6 and r=0.52, p=0.007 at the whole-brain level for hs-CRP). Also, BGU 
during clamp was positively associated with the aromatic amino acid, phenylalanine 
(r=0.60, p=0.001) and the branched-chained amino acid leucine (r=0.59, p=0.002) 
(N=26) (Figure 12). The correlation between BGU and phenylalanine and leucine 
remained significant after adjusting for the M-value (r=0.68, p=0.01, and r=0.67, 
p=0.01, respectively).  
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Figure 12. A: Spearman correlations between insulin-stimulated ROIs of BGU and fasting 
metabolites (N=26). CER-A, anterior cerebellum; CER-P, posterior cerebellum; FRO, 
frontal lobe; LIMB, limbic lobe; MID, midbrain; OCC, occipital lobe; PAR, parietal lobe; 
TEMP, temporal lobe. DHA, 22:6, docosahexaenoic acid; DHAFA, ratio of 22:6, 
docosahexaenoic acid to total fatty acids; FAw3, Omega-3 fatty acids; FAw3FA, ratio of 
Omega-3 fatty acids to total fatty acids; Glc, glucose; Gln, glutamine; Glol, glycerol; Gp, 
glycoprotein acetylation; HDLC, total cholesterol in HDL; HDL2C, total cholesterol in 
HDL2; His, histidine; LDLTG, triglycerides in LDL; Leu, leucine; MUFA, 
monounsaturated fatty acids; MUFAFA, ratio of monounsaturated fatty acids to total 
fatty acids; Phe, phenylalanine; PUFAFA, ratio of polyunsaturated fatty acids to total 
fatty acids; Pyr, pyruvate; Serum-TG, serum total triglycerides; SFAFA, ratio of 
saturated fatty acids to total fatty acids; Tyr, tyrosine; UnSat, estimated degree of 
unsaturation; VLDLC, total cholesterol in VLDL. 
After surgery 
Six months after surgery, obese subjects had achieved significant weight loss (~24% 
of their initial body weight), but their BMI remained significantly higher compared 
to the controls. The M-value doubled, and serum IL-6 and CRP levels decreased 
significantly. Fasting EGP decreased significantly, but insulin-suppressed EGP 
showed a small, non-significant decrease. BGU was decreased (~5%) but was still 
higher than in controls and positively associated with EGP (r=0.56, p=0.02) (Figure 
13).  
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Figure 13. SPM images of the association between insulin-stimulated BGU and insulin-suppressed 
EGP in the obese subjects postoperatively and the corresponding scatterplot. In the 
scatterplot the mean BGU from the significant voxels only is presented (BGU*). 
Follow-up 
Patients were weight-stable at two and three years of follow-up (BMI: 32.1 [4.1] and 
32.1 [3.8] kg/m2, respectively). A higher BGU during clamp before surgery was 
associated with a smaller improvement of fasting plasma glucose levels at two years 
(r=-0.63, p=0.006) (Figure 14). This association persisted after correcting for 
baseline BMI (r=-0.66, p=0.01) or M-value (r=-0.72, p=0.02) (N=17). In 13 subjects 
who had complete follow-up data for up to 3 years, higher baseline values of BGU 
during clamp were still predictive of smaller postoperative decrements of fasting 
glucose levels (r=-0.71, p=0.006). On the contrary, baseline BGU was unrelated to 
BMI or HbA1c at follow-up. 
 
Figure 14. SPM images of the association between BGU during clamp at baseline and change in 
plasma glucose at two years of follow-up in 17 obese subjects and the corresponding 
scatterplot. P values <0.05 cluster level, FDR corrected 
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5.2 Brain glucose uptake correlates positively with 
parameters of beta cell function (II) 
The characteristics of the study participants are reported in Table 3. 
Table 3. Anthropometric and biochemical characteristics of the study participants. 
 Clamp [18F]FDG (a) Fasting [18F]FTHA (b) Fasting [18F]FDG (c) 
 Non-T2D T2D Non-T2D T2D Non-T2D T2D 
M/F 9/43 4/11 0/26 0/8 10/29 0/6 
Age (years) 45 ± 10 49 ± 7 44 ± 12 45 ± 8 44 ± 9 54 ± 5* 
BMI  
(kg.m-2) 
27.4 
[17.7] 
34.0 
[12.1]* 
27.7 
[17.8] 
39.1 
[18.0]* 
32.0 
[10.0] 
41.5 
[15.0] 
HbA1c (%) 5.5 [0.5] 5.9 [0.7]* 5.6 [0.6] 6.2 [1.0]* 5.8 [0.4] 6.8 [0.6]* 
M value  
(μmol.kgFFM-1.min-1) 
39.4 
[30.0] 
19.3 
[14.7]* 
 
- 
 
- 
32.6 
[32.6] 
19.8 
[23.3] 
Plasma insulin  
(pmol-L-1) 
476 
[221] 
609 
[161] 
40 
[47] 
119 
[13]* 
53 
[44] 
112 
[63]* 
Serum FFA 
(mmol.L-1) 
0.05 
[0.05] 
0.1 
[0.06]* 
0.61 
[0.40] 
0.79 
[0.44] 
0.49 
[0.31] 
0.61 
[0.26] 
Basal ISR  
(pmol.min-1.m-2) 
86 
[55] 
135 
[38]* 
81 
[44] 
152 
[85]* 
91 
[66] 
118 
[72] 
Total insulin output  
(nmol.m-2) 
40 
[22] 
48 
[16] 
44 
[18] 
44 
[11] 
 
- 
 
- 
β-GS 
(pmol.min-1.m-2.mM-1) 
119 
[107] 
48 
[38]* 
117 
[101] 
42 
[40]* 
 
- 
 
- 
Rate sensitivity 
(pmol.m-2.mM-1) 
506 
[1363] 
651 
[1057] 
922 
[1091] 
349 
[410]* 
 
- 
 
- 
Potentiation ratio 1.3 [0.7] 1.3 [1.1] 1.4 [1.6] 1.2 [0.8] - - 
Brain substrate uptake 
(μmol.100g-1.min-1)# 
25.7 
[10.9] 
28.3 
[8.0]* 
1.0 
[0.6] 
1.1 
[0.8] 
20.5 
[5.4] 
17.5 
[4.1] 
Entries are mean±SD, or median [IQR]; #glucose, or FFA as appropriate. * p value <0.05, for the 
comparison between non-T2D and T2D. BMI = body mass index; ISR = insulin secretion rate; β-
GS = ß-cell glucose sensitivity; T2D = type 2 diabetes 
Insulin-stimulated brain glucose uptake and whole body glucose disposal 
(dataset a) 
Cross-sectionally (N=67), insulin-stimulated BGU correlated negatively with the 
degree of insulin sensitivity (M-value) (r=-0.40, p=0.001) and positively with the 
average (steady-state) FFA concentration (r=0.42, p=0.0007).  
Brain glucose uptake and ß-cell function (dataset a and c) 
Insulin-stimulated BGU correlated positively with basal ISR (r=0.44, p=0.0002) and 
total insulin output (r=0.36, p=0.003). Contrastingly, no significant association was 
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found between fasting brain glucose uptake and basal ISR (N=45). With regard to 
the dynamic parameters of ß-cell function, only potentiation (not ß-cell glucose 
sensitivity or rate sensitivity) was directly related to BGU (r=0.24, p=0.048). 
These results were driven by the subjects not affected by T2D (non-T2D) 
because when we divided the population into non-T2D (N=52) and T2D (N=15), 
said associations remained significant only in the non-T2D (r=0.51, p=0.0008 for 
basal ISR and r=0.51, p=0.0008 for total insulin output) (Figure 15).  
 
Figure 15. Brain clusters (as defined by FDR-corrected SPM two-sample t-test) for the association 
between brain glucose uptake (BGU) during clamp and basal insulin secretion rate (ISR) 
(A) and total insulin output (B) in non-T2D. No correlation between BGU during clamp 
and basal insulin secretion rate (ISR) (C) or total insulin output in T2D (D). No correlation 
between fasting BGU and basal insulin secretion rate (E). For the corresponding 
scatterplots, the global ROI was extracted and used.  
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Interestingly, potentiation behaved differently, and whereas BGU and potentiation 
were directly related in the 52 non-T2D (r=0.33, p=0.02), in the T2D group there 
was a significant inverse correlation between BGU and PFR (r=-0.61, p=0.02) 
(Figure 16). 
 
Figure 16. Brain clusters (as defined by FDR-corrected SPM one-sample t-test) for the association 
between brain glucose uptake (BGU) during clamp and potentiation of insulin secretion 
in non-T2D (A) and T2D (B) and the corresponding scatterplots. Brain clusters (as 
defined by FDR-corrected SPM one-sample t-test) for the association between brain 
fatty acid uptake (BFAU) and potentiation (C). Due to the non-global effects, the occipital 
ROI was extracted and used in the scatterplot 
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In the non-T2D group, we applied a stepwise selection approach in order to find the 
optimal models of prediction of BGU during clamp. In the models, we included 
possible confounders, such as the time interval from FDG injection to the brain scan, 
the fact that three different scanners were used, BMI, M-value, steady-state plasma 
insulin levels and one parameter of ß-cell function in use at the time. In all cases, the 
parameters of ß-cell function (basal ISR, total insulin output, and potentiation) were 
included in the optimal prediction models of BGU during clamp. In the same line, 
after partialing for insulin sensitivity (basal ISR, PFR) or BMI (for total insulin 
output), the associations between BGU and basal ISR (r=0.32, p= 0.024), PFR 
(r=0.44, p= 0.001) and total insulin output (r=0.37, p= 0.008) remained significant.  
Regional findings  
In the 52 non-T2D, the positive correlations between BGU and basal ISR as well as 
total insulin output were confirmed also in the various regions of interest examined 
(Table 4). The positive and negative correlations between BGU and PFR in non-
T2D and in patients with T2D were also confirmed in most ROIs.  
Table 4. Correlations between BGU and basal ISR, total insulin output, and potentiation (dataset 
a). 
 Basal ISR TIS PFR 
     non-T2D T2D 
 p value r p value r p value rho p value rho 
Cerebellum Ant. 0.005 0.39 0.007 0.37 0.02 0.32 0.02 -0.61 
Cerebellum Post. 0.007 0.37 0.007 0.37 0.02 0.33 0.04 -0.53 
Occipital Lobe 0.002 0.43 0.002 0.43 0.01 0.34 0.02 -0.60 
Parietal Lobe 0.001 0.45 0.001 0.46 0.03 0.31 ns - 
Temporal Lobe 0.003 0.41 0.005 0.39 0.03 0.30 0.03 -0.56 
Frontal Lobe 0.002 0.43 0.002 0.42 0.03 0.30 ns - 
Limbic Lobe 0.002 0.42 0.005 0.39 0.03 0.31 0.03 -0.56 
Midbrain 0.002 0.43 0.004 0.40 0.04 0.29 0.02 -0.60 
r: correlation coefficient; rho: Spearman correlation coefficient. Cerebellum Ant= Cerebellum 
anterior; Cerebellum Post=Cerebellum posterior 
Brain FFA uptake and ß-cell function (b) 
Brain FFA uptake (BFAU) was positively associated with BMI (r=0.5, p=0.003) and 
other measures of adiposity. BFAU also correlated with basal ISR (r=0.39, p=0.02) 
and, in an inverse manner, with potentiation (r=-0.36, p=0.04) (Figure 16C). Similar 
trends of these associations were found also when dividing the population into non-
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T2D and subjects with T2D (N=8), even though the associations in the T2D group 
did not reach statistical significance probably because of low numerosity.  
Regional findings 
The correlations between BFAU and the aforementioned parameters of ß-cell 
function were confirmed also in the various regions of interest examined (Table 5).  
Table 5. Correlations between BFAU and BISR and Potentiation. 
  Basal ISR Potentiation 
  p-value r p-value rho 
Cerebellum Anterior 0.03 0.38 0.02 -0.41 
Cerebellum Posterior 0.04 0.36 0.04 -0.35 
Occipital Lobe 0.03 0.38 0.02 -0.41 
Parietal Lobe 0.02 0.39 0.01 -0.42 
Temporal Lobe 0.02 0.39 0.01 -0.43 
Frontal Lobe 0.02 0.39 0.01 -0.42 
Limbic Lobe 0.01 0.42 0.01 -0.42 
Midbrain 0.03 0.38 0.02 -0.39 
r: correlation coefficient; rho: Spearman correlation coefficient 
The following scheme summarizes the found associations (Figure 17). 
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Figure 17. Schematic representation of the separate influence of substrate levels on insulin 
secretion; directly on the ß-cell and indirectly via brain substrate uptake. Assuming that 
the brain “drives” the observed correlations, increased BGU in conditions of insulin 
stimulation may lead to enhanced insulin secretion in non-T2D and increased or 
decreased potentiation in non-T2D and T2D, respectively. Increased BFAU during 
fasting may stimulate insulin secretion, but downregulate potentiation. The net effect of 
these phenomena would result in enhanced insulin secretion in non-T2D, which in the 
short term would restore normal plasma glucose levels. However, an activated brain-
pancreas axis might also have long-term effects. In T2D, the brain’s control over insulin 
secretion seems either lost or reversed (see also text).  
5.3 Brain fatty acid uptake is higher in obese 
subjects, but it does not decrease six months 
after bariatric surgery (III). 
Clinical and metabolic characteristics of the study participants  
By definition, obese participants had higher measures of adiposity (WHR, fat mass, 
and BMI), higher fasting FFA and glycerol levels, and worse insulin sensitivity, 
compared to age-matched lean controls. Obese participants also had high circulating 
inflammatory markers (Table 6). 
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Table 6. Anthropometric and biochemical characteristics of the study subjects. 
 
Controls 
(n = 14) 
Obese  
Before (n = 24) After (n = 21) po 
Age (years) 45 ± 12 43 ± 10 - - 
BMI (kg/m2) 22.6 ± 2.8 41.1 ± 4.2* 31.8 ± 4.2# <0.0001 
WHR (cm/cm) 0.77 ± 0.05 0.89 ± 0.07* 0.87 ± 0.09# 0.04 
Fat mass (kg) 19 ± 6 56 ± 10* 37 ± 9# <0.0001 
Fat-free mass (kg) 42 ± 4 56 ± 9* 49 ± 6# <0.0001 
Triglycerides (mmol.L-1) 0.66 ± 0.32 1.18 ± 0.42* 1.09 ± 0.54# ns 
Glucose (mmol.L-1) 5.13 ± 0.34 5.71 ± 1.03* 5.30 ± 0.79 ns 
Insulin (µU.mL-1) 3.0 [3.5] 9.5 [10.8]* 4.0 [3.0] (0.06) 
OGIS (ml.min-1.m-2) 426 [91] 351 [67] * 444 [63] <0.0001 
HbA1c (%) 5.6±0.3 6.0±0.7* 5.4±0.4 <0.0001 
FFA (mmol.L-1) 0.55 ± 0.17 0.80 ± 0.22* 0.77 ± 0.17# ns 
Glycerol (µmol/L) 67 ± 23 113 ± 31* 108 ± 53# 0.01 
hs-CRP (mg/L) 0.4 [0.6] 2.9 [3.8]* 0.9 [1.4]# 0.003 
IL-8 (pg/ml) 4.14 [1.5] 4.6 [2.6] 4.4 [2.3] ns 
TNF-α (pg/ml) 2.4 [1.8] 4.4 [1.6]* 3.7 [1.9] 0.07 
Leptin (ng/ml) 5.3 [5.3] 36.8 [21.3]* 15.4 [14.2] <0.0001 
Data are mean ± SD or median [IQR]; * p < 0.05 obese vs. controls; ° after vs. before surgery; # p 
< 0.05 obese after surgery vs. controls. 
Before surgery 
Brain FFA uptake was higher in the obese subjects than in the lean subjects (1.12 
[0.61] vs. 0.72 [0.50] µmol.100g-1.min-1, p=0.002) (Figure 18). This increase was 
driven by higher FFA availability (0.80 ± 0.22 vs. 0.55 ± 0.17 mmol/L, p=0.001) as 
the fractional uptake rates were similar in the two groups (0.017 [0.005] vs. 0.018 
[0.006] min-1 in the obese and in the lean subjects, respectively, ns). In contrast, the 
hypothalamus/amygdala FLAIR ratio did not differ between obese and control 
subjects (Table 7).  
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Figure 18. Brain clusters (as defined by FDR-corrected SPM one-sample t-test) for the comparison 
of brain fatty acid uptake (BFAU) between the two groups, and the corresponding bar 
graphs. The global ROI was extracted and used. 
Table 7. Brain fatty acid uptake and the FLAIR hypothalamus/amygdala signal ratio. 
 
Controls 
(n=14) 
Obese  
Before (n=24) After (n=21) p* 
Global (µmol/100g/min) 0.72 [0.50] 1.12 [0.61] 1.09 [0.39]# 0.002 
Cerebellum ant. (µmol/100g/min) 0.77 [0.57] 1.32 [0.75] 1.21 [0.49]# 0.001 
Cerebellum post.(µmol/100g/min) 0.75 [0.61] 1.19 [0.73] 1.13 [0.48] 0.006 
Frontal Lobe (µmol/100g/min) 0.67 [0.50] 1.04 [0.55] 0.99 [0.34] # 0.002 
Limbic Lobe (µmol/100g/min) 0.71 [0.48] 1.11 [0.61] 1.06 [0.45] # 0.002 
Midbrain (µmol/100g/min) 0.75 [0.52] 1.21 [0.71] 1.12 [0.42] # 0.002 
Occipital Lobe (µmol/100g/min) 0.79 [0.55] 1.21 [0.65] 1.17 [0.40] # 0.003 
Parietal Lobe (µmol/100g/min) 0.75 [0.53] 1.17 [0.64] 1.14 [0.39] # 0.001 
Temporal Lobe (µmol/100g/min) 0.72 [0.48] 1.09 [0.58] 1.05 [0.38] # 0.002 
Hypothalamus/amygdala signal 1.07 [0.04] 1.07 [0.08] 1.07 [0.09] ns 
Data are median [IQR]; *obese vs. controls; ° p < 0.05 after vs. before surgery; # p < 0.05 obese 
after surgery vs. controls 
After surgery 
Post-surgical data were available for 21 subjects since three subjects did not 
undergo surgery. Six months after the operation participants had lost a significant 
amount of body weight (26 ± 8 kg). Insulin sensitivity (as indexed by OGIS), 
HbA1c levels, and circulating inflammatory markers had improved (Table 6). 
Because of the ongoing catabolic state, serum FFA levels were not decreased (0.80 
± 0.22 vs. 0.77 ± 0.17 mmol/L, ns). BFAU showed only a small, but not statistically 
significant, decrease (Figure 19). The hypothalamus/amygdala FLAIR ratio was 
unchanged.  
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Figure 19. No difference in BFAU was found six months after bariatric surgery. The global ROI 
was extracted and used. 
Correlations 
Cross-sectionally, baseline BFAU was positively associated with BMI (r=0.47, 
p=0.003) and other markers of adiposity such as fat mass (r=0.45, p=0.006) and 
leptin (r=0.54, p=0.0008), and negatively associated with OGIS (r=-0.45, p=0.007). 
In contrast, the hypothalamus/amygdala FLAIR ratio did not correlate with BMI, 
circulating inflammatory markers, or BFAU (Figure 20). 
 
 
Figure 20. (A) A Flair images showing the region of interest positioning. The hypothalamus/ 
amygdala signal ratio did not correlate with BFAU, BMI, or IL-8 (B-D).  
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In the 18 subjects of whom we had follow-up data, baseline BFAU predicted higher 
plasma glucose levels at two years of follow up (Figure 21). The association 
remained significant after adjusting for baseline plasma glucose levels. 
 
Figure 21. Brain clusters (as defined by FDR-corrected SPM one-sample t-test) for the association 
between (BFAU) and δ glucose at two years follow-up. The global ROI was extracted 
and used. 
Since in the same PET study radioactivity from several organs/tissues was acquired, 
it is of interest to compare FFA uptake across different tissues. Per unit tissue mass, 
the brain was the 4th tissue in order of magnitude to use FFAs after the liver, heart, 
and kidney (Figure 22). However, by multiplying tissue uptake rates by the 
respective total mass, the contribution of the brain in total FFA uptake becomes 
marginal and similar in magnitude to visceral fat. 
 
Figure 22. FFA uptake in several tissues measured in the same subjects. Brain FFA uptake per 
unit tissue mass is fourth after hepatic, cardiac and renal FFA uptake. Obese (red 
colour); lean controls (blue). * indicates p < 0.05 between obese and lean individuals. 
SC: abdominal subcutaneous fat, VF: visceral fat, SM: skeletal muscle, LV: left ventricle. 
Entries are mean±SE.
 60
6 Discussion 
There are several lines of research in a preclinical setting that have shown that the 
brain is involved in the control of whole-body homeostasis, and more specifically of 
the determinants of glucose tolerance. Human data are scanty, but necessary in order 
to translate these findings into humans, and gain further insight into the 
pathophysiology of metabolic diseases, which may eventually lead to the discovery 
of new potential treatments. The work in this thesis focused on studying the role of 
the brain in the orchestration of whole-body homeostasis. We used positron emission 
tomography and two tracers ([18F]FDG and [18F]FTHA) in order to study the 
connections of the brain to the peripheral determinants of glucose tolerance, namely 
insulin sensitivity and insulin secretion. Moreover in two different datasets we were 
able to see that high brain substrate utilization (glucose and fatty acids) predicts a 
worse glycemic control at follow-up.  
Regarding the association between BGU and EGP (study I), we found that this 
brain-liver axis was present only in obese/insulin resistant subjects, but not in the 
lean controls. Similar findings were also reported from our group in another 
population of obese, middle-aged men (Latva-Rasku et al., 2017). The association 
between BGU and EGP persisted also after significant weight loss, six months after 
BS. Of note, even though the obese had achieved significant weight loss at the time 
of the post-operative studies, they still remained obese (mean BMI 33.1±3.8 kg.m-2). 
This finding seems to be in line with results from experimental settings where 
intranasal insulin has been applied and EGP has been measured with the gold-
standard of D-[6,6-2H]glucose infusion, whereby it was shown that on top of the 
euglycemic hyperinsulinemic clamp, intranasal insulin application suppresses EGP 
in lean but not in overweight subjects (Heni et al., 2017). Thus, if we combine the 
results of the two different groups, which used different neuroimaging approaches, 
it emerges that in lean (insulin sensitive subjects) there is no association between 
BGU and EGP, and when intranasal insulin is given, EGP is suppressed. On the 
contrary, in the obese (insulin resistant) subjects in which we found a positive 
association between BGU and EGP, intranasal insulin does not suppress EGP, 
indicating insulin resistance of the brain-liver axis. Assuming that the brain drives 
the observed association, one may hypothesize that the brain is driving the increased 
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EGP in the obese, and it is resistant to insulin to suppress EGP after intranasal insulin 
administration. It should also be noted that the Tubinghen group has also shown that 
during fasting conditions intranasal insulin application does not affect EGP 
(Gancheva et al., 2015), and also in our data BGU and EGP in the fasting state do 
not correlate.  
Taken together, one might hypothesize that an important prerequisite for this 
brain-liver axis to be present are plasma insulin levels in the post-meal range. Of 
course, the exact mechanism for this crosstalk in humans is not known. Preclinical 
data suggest, though, that the phosphatidylinositol-3-kinase (PI3K) pathway is 
involved since in rats the effect of systemic high insulin levels on suppressing EGP 
was abolished after the ICV administration of PI3K inhibitors (Obici et al., 2002a). 
In that study, a similar effect on abolishing the EGP suppression was seen after 
central administration of antibodies against insulin or against the insulin receptor, 
but not when an antagonist of the mitogen-activated protein (MAP) kinase was given 
(Obici et al., 2002a). It has also been shown that activation of the hypothalamic KATP 
channels is involved in the suppression of EGP (Pocai et al., 2005). Other lines of 
research have provided evidence that central glucose sensing, involving glucose-
regulated neurons as well as astrocytes, may also modulate EGP (Marty et al., 2007). 
Of interest, baseline insulin-stimulated BGU predicted worse glycemic control 
at two and three years of follow-up (after also accounting for baseline plasma glucose 
levels). On the contrary insulin-stimulated BGU did not predict δBMI, δBW, or 
δHbA1c at follow-up. Thus, insulin-stimulated BGU predicted only plasma glycemia, 
i.e. the parameter most dependent on EGP.  
Similar findings of baseline brain substrate uptake predicting worse glycemic 
control at two years of follow-up were found also in the third study, where a similar 
group of morbidly obese women was studied before and after BS. The difference 
was that this time we had measured brain fatty acid uptake, during fasting conditions. 
These data suggest that high brain substrate uptake can predict, and perhaps lead to, 
metabolic deterioration in the future. Other research groups using different 
techniques have provided similar evidence. For instance, in the TULIP study, (an 
intervention study with lifestyle modification targeting weight loss), it was shown 
that central insulin resistance (defined in this study as blunted cerebrocortical insulin 
effect assessed by magnetoencephalography) was associated with a smaller decrease 
in total and visceral adipose tissue and fasting plasma glucose levels as well as worse 
adherence to the lifestyle recommendations (Tschritter et al., 2012). In an extended 
follow-up of nearly 10 years, the same group showed that central insulin resistance 
at baseline predicted weight regain (Kullmann et al., 2020). 
Of course, as it will also be discussed in the limitations section, correlations do 
not prove cause-effect. On the other hand, it is of interest that both these two datasets 
showed this prediction of fasting glycemia. Studies with longer follow-up are 
Eleni Rebelos 
 62
needed, to evaluate whether baseline high brain substrate uptake predicts worse 
metabolic outcome in the future. Similar longitudinal studies in subjects who have 
not undergone BS, are currently few and warranted.  
Regarding the association between BGU and the parameters of ß-cell function 
(study II), there is mounting preclinical evidence (already 50-60 years old), 
suggesting that the brain may also influence insulin secretion. We also addressed 
whether brain substrate uptake associates with insulin secretion. For these studies in 
order to increase statistical power, we pooled and re-analyzed the data of all subjects 
in the same way from whom brain [18F]FDG radioactivity was acquired, and who 
also underwent an OGTT with adequate blood sampling (at least 0, 30, 60, 90, 120) 
for OGTT modeling. 
Based on the data of dataset (a), we found that insulin-stimulated BGU in non-
T2D correlated positively with BISR, TIS, and potentiation. No associations were 
found regarding BGU and insulin secretion in a small group of 15 subjects with T2D. 
Regarding BISR and TIS, the correlations with insulin-stimulated BGU may be 
expected since in insulin resistance both increased insulin secretion and increased 
insulin-stimulated BGU have been reported. Of interest though, our results remained 
significant when accounting for the degree of insulin sensitivity. Furthermore, brain 
glucose uptake was also directly related to potentiation of insulin release in non-T2D 
(also after controlling for insulin resistance), and inversely in subjects with T2D. 
These correlations between brain substrate uptake and potentiation are of particular 
interest, since apart from the antecedent glycaemia and the incretins a neural factor 
has been also suggested to account for potentiation. Moreover, subjects with T2D, 
had an inverse correlation between BGU and PFR, thus the patterns of associations 
were clearly different for potentiation in subjects with T2D and non-T2D. 
Collectively, therefore, these results are compatible with the notion that ß-cell 
function may be modulated by the brain. In T2D this ‘’brain control’’ is either lost 
or reversed. This suggestion is in line with growing evidence that points to an 
alternative course in the natural history of glucose intolerance, whereby insulin 
hypersecretion may occur independently of insulin resistance (Trico et al., 2018) as 
a result of influences deriving from the central nervous system.  
After detecting these findings when using [18F]FDG-PET, we hypothesized that 
brain substrate uptake when using a fatty acid tracer could also correlate with the 
parameters of ß-cell function. We hypothesized so, because FFA are known to 
stimulate insulin secretion through direct effect on the pancreas (Rebelos et al., 
2015). However, fatty acids also cross the BBB and have central effects. The current 
[18F]FTHA-PET data show that brain FFA uptake under fasting conditions is directly 
associated with basal insulin secretion rate and negatively associated with 
potentiation. Thus, the uptake of glucose under insulinized conditions and the uptake 
of FFA under fasting conditions appear to be co-stimulatory signals in the brain for 
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insulin release. However, brain FFA uptake is a negative signal for potentiation of 
insulin release. This disassociation of substrate influence on insulin secretion vs. 
potentiation of insulin secretion is supported by recent data showing that potentiation 
of insulin release is impaired in insulin resistant individuals (who typically have 
elevated FFA levels) (Rebelos et al., 2017), and that acute elevations of plasma FFA 
impair incretin-induced potentiation of insulin release (Astiarraga et al., 2018). The 
idea of a separate influence of substrate levels on insulin secretion – directly on the 
ß-cell and indirectly via brain substrate uptake – is schematically summarized in 
Figure 17.  
In dataset (c) of this study (study II), we assessed whether BGU during fasting 
correlates with BISR, but no such association was found. Thus, the associations 
between brain substrate uptake and the parameters of ß-cell function were found only 
in conditions where insulin resistance has an effect on up regulating brain substrate 
uptake (clamp conditions when studying BGU, fasting conditions when studying 
BFAU).  
It is possible that the increased glucose availability to selected brain regions 
induced by insulin is read as a signal to upgrade global ß-cell function in order to 
defend/restore normal glucose homeostasis. In the fasting state, on the other hand, 
the increased brain FFA uptake restrains ß-cell function by downgrading 
potentiation. This interpretation (outlined in Figure 17) is based on associations and 
is, therefore, speculative. However, there is supportive evidence in the literature. 
Even though our data do not include any information with long follow-up, one might 
hypothesize that the brain-pancreas axis could have beneficial short-term effects 
restoring normal plasma glucose levels, but in the long term, it might ultimately 
contribute to the worsening of insulin resistance and/or ß-cell overload (Figure 17).  
The mechanism of the brain- pancreas axis that we report is not known. Animal 
studies, though, have shown that astrocytes are involved in the control of both insulin 
and glucagon secretion after intracarotid injection of glucose and an 
intracerebroventricular injection of 2-deoxy-D-glucose, respectively (Guillod-
Maximin et al., 2004; Marty et al., 2005). 
In the last study (study III), we have shown that morbidly obese subjects have 
higher brain fatty acid uptake than lean individuals. Thus, we replicated and 
extended our original findings regarding metabolic syndrome (Karmi et al., 2010). 
In our previous study, the lean group consisted of men only, whereas the metabolic 
syndrome group consisted of both men and women. For this reason, we could not 
rule out differences in BFAU between genders. Because women undergo bariatric 
surgery more frequently than men, we investigated differences in morbidly obese vs. 
lean women only.  
Brain FFA uptake ranged from 0.3-1.3 µmol.100mL-1.min-1, which translates to 
a whole-brain uptake of 4-14 µmol.min-1. The fate of the uptaken FFAs from the 
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brain, is not completely known, but as discussed by Schönfeld and Reiser in their 
elegant review (Schonfeld and Reiser 2013), brain fatty acids can be either esterified 
to membrane lipids or undergo β-oxidation in the mitochondria. Furthermore, the 
authors argue that excessive oxidation of fatty acids could be detrimental to the 
“economy” of the brain cells. Accordingly, our previous study using both [18F]-
FTHA-PET and [11C]-palmitate-PET (the first tracking total FFA uptake, the latter 
non-oxidative metabolism) concluded that not all of the uptaken fatty acids are 
oxidized by the brain (Karmi et al., 2010). In that study the oxidative part of FFA 
uptake (subtracting the non-oxidative metabolism from the total FFA uptake) would 
be roughly 70% of the total FFA uptake. On the other hand, if we take the average 
figure of 9 µmol.min-1 of brain FFA uptake from our data and we consider the 
CMRO2 (  ̴140 µmol/100g/min) and CBF (  ̴44 mL/100g/min) values reported in the 
study by Goyal et al. (see also page 18) (Goyal et al., 2017) assuming a normal 
hematocrit of 0.45 and a brain volume of   ̴1400 ml, it emerges that if FFAs were 
completely oxidized by the brain, they would require ~202 µmol/min of O2. 
However, the complete oxidation of 22 µmol/100g/min glucose, which is the average 
BGU under fasting conditions that Goyal et al. reported, leaves only 112 µmol/min 
of O2 consumption unaccounted for (considering an oxygen to glucose ratio close to 
6) and potentially attributable to other substances. Thus, based on these calculations, 
approximately half of the uptaken FFA from the brain is used for non-oxidative 
purposes. In both calculations, several assumptions, though, are made, which may 
explain why the estimated percentages of oxidative fatty acid uptake do not perfectly 
match. Moreover, since, in this PET study, fatty acid uptake rates were quantified 
during the same PET session from several tissues (including skeletal muscle, liver, 
heart and adipose tissue), we were able to compare the contribution of each tissue on 
the handling of FFA. Using the fatty acid analog [18F]FTHA, we found that brain 
FFA uptake ranges between 0.3-1.3 µmol.100mL-1.min-1, which translates to a 
whole-brain uptake of 4-14 µmol.min-1. By comparison with previous PET studies 
using [18F]FTHA (Dadson et al., 2017; Hannukainen et al., 2018; Immonen et al., 
2018; Rebelos et al., 2019), we can conclude that the brain has a relatively high 
tissue-specific FFA uptake (fourth after liver, kidney and heart but before adipose 
tissue or resting skeletal muscle). (Figure 22).  
In all the studies presented in this thesis, we have hypothesized that the results 
could be mediated (at least to some extent) through astrocytes. This “astrocyte-
centric” approach derives from the astrocytes’ characteristic of representing the 
energy hubs of the brain. There are several reasons for taking this “astrocyte-centric” 
approach. First, astrocytes express several hormonal receptors, among which GLP-
1, glucagon, and insulin, and have been shown in preclinical studies to participate in 
the handling of both insulin secretion, and EGP. Second, a recent publication has 
shown that the glucose uptake that is measured with [18F]FDG-PET is driven by 
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astrocytes (Zimmer et al., 2017). This is in accord with what was originally proposed 
as the astrocyte-neuron lactate shuttle (ANLS), whereby astrocytes convert glucose 
into lactate and supply lactate to neurons (Pellerin and Magistretti 1994). As 
discussed in the introduction, this metabolic paradigm is controversial. However, the 
controversy mainly regards how the shuttle is closed, but that glucose is taken up by 
astrocytes and that they provide lactate to neurons seems a consolidated finding. 
Third, another well-known fact about astrocytes, is that in case of 
neuroinflammation, they proliferate and they become activated, a phenomenon 
known as astrogliosis. It is consolidated that obesity is linked with low-grade 
systemic inflammation (Hotamisligil 2006). However, animal studies have shown 
that a high-fat diet induces rapid neuroinflammation; in fact this process is so quick 
that it precedes the development of systemic inflammation (Thaler et al., 2012). 
Altogether, a plausible interpretation of our data could be that the increased brain 
glucose uptake in obesity is, at least in part, due to obesity-induced astrocyte 
proliferation.  
In this respect, in Study III we analyzed the FLAIR MRI hypothalamus/ amygdala 
hyperintensity signal. This signal has been described to depict central inflammation. 
However, it is not specific, since similar MRI hyperintensities have been described 
also with edema, infection, and tumors which can have a similar appearance (Thaler 
et al., 2012). Moreover, it is not clear whether it is supposed to represent absolute 
hypothalamic inflammation or relative to amygdala hypothalamic inflammation. We 
hypothesized that BFAU could also be attributed to central inflammation, considering 
that the astrocytes are the main handler of fatty acids in the CNS. Contrary to our 
hypothesis, we did not find any association between BFAU and the 
hypothalamus/amygdala signal ratio. Moreover, we were not able to reproduce the 
previous findings by other groups regarding BMI and inflammatory markers (Schur et 
al., 2015; Thaler et al., 2012). This discrepancy could, in part be attributed to technical 
reasons. The hypothalamus is a very small brain region, and our FLAIR-MRI protocol 
was designed to cover the whole brain with 5-mm thick slices. These relatively thick 
slices may have caused ROI malpositioning and precluded sensitivity for subtle 
changes in the hypothalamic FLAIR signal. We found a small measurement error 
(inter-rater variability), yet only moderate intraclass correlations (0.63). Previous 
studies have not assessed the reliability of hypothalamic FLAIR measurements. This 
pattern of results suggests insufficient between-subject variability (i.e., identifiability 
of individuals) to make this ratio an optimal biomarker in metabolic studies. Apart 
from the pros and the limitations of this method, our hypothesis of neuroinflammation 
would require an imaging method that can assess the whole brain, and not be restricted 
to the hypothalamus. This is both because astrocytes are widely distributed in the CNS 
and also because the increased BGU in obese subjects is global and not restricted to 
the hypothalamic region.  
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6.1 Strengths, limitations 
The strengths of the current studies are their relatively big numbers of study subjects, 
across a wide range of age, BMI, and insulin sensitivity. Baseline and follow-up data 
were combined showing that high brain substrate at baseline predicts metabolic 
outcome at follow-up, thus further underlying the importance of studying brain 
metabolic rates in humans. Moreover, the fact that state-of-the art techniques, such 
as positron emission tomography and the euglycemic hyperinsulinemic clamp have 
been applied in studying in vivo metabolism in humans, is a considerable strength. 
One of the main limitations of the presented studies (I- II) is that they mainly 
presented correlational data and thus, cannot prove causality.  
Still, while working on these data important deepening of our understanding has 
occurred. Based on the preliminary results from study I, and available literature, we 
formulated the hypothesis that the increased BGU in the obese/insulin resistant 
subjects could be driven by central inflammation. Based on this hypothesis, we are 
already conducting a clinical and preclinical study to address whether a) central 
inflammation occurs in morbidly obese subjects, b) whether the increased BGU is 
due to central inflammation, and c) whether central inflammation improves after 
significant weight loss.  
In study I, the method used to calculate EGP gave in some cases negative values 
in the experiments performed during euglycemic hyperinsulinemia. Since negative 
values are not physiological, we considered these negative values to be representing 
the cases with the highest suppression of EGP from insulin. It follows that even 
though the method that we have used for the calculation of EGP is validated against 
the gold standard of D-[6,6-2H] glucose, it is not as precise as the gold standard. 
In study II, we chose to examine whether there is any association between BGU 
and the parameters of ß-cell function in a dataset where we pooled data from smaller 
studies in which the timing of brain radioactivity acquisition varied. We applied a 
generally accepted statistical method to account for this discrepancy in the data by 
accounting for the time interval from [18F]FDG injection to the brain scan. However, 
whether this statistical correction truly accounts for the difference in BGU when 
measured immediately after [18F]FDG injection or later, is beyond the scope of our 
study.  
Another important limitation of the current work is that the hypothalamus, a 
brain region of specific interest could not be adequately studied. The hypothalamus 
is a very small brain region and because of the physics of PET, minuscule anatomical 
regions cannot be analyzed with sufficient resolution (Teräs 2008).  
Furthermore, in study III, we only used MRI to probe central nervous system 
inflammation. Though the analysis was performed by two independent 
neuroradiologists, with good agreement values between them, the results indicate 
that MRI may not be the optimal technique to detect brain inflammation.  
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In this study, only women were studied because of the fact that, in general, more 
women undergo bariatric surgery in Finland than men. Keeping the gender bias in 
mind, the results regarding brain fatty acid uptake should be generalized to men with 
caution, even though, the previous study by Karmi et al. reported similar BFAU rates 
also in men (Karmi et al., 2010). 
6.2 Clinical implications and future perspectives 
These studies deepen our knowledge of the pathophysiology of insulin resistance 
and the alterations that occur in the body and specifically in the brain with 
obesity/insulin resistance a bit more. We have shown that in the context of insulin 
resistance, there is increased substrate uptake from the brain (both glucose and free 
fatty acids). BGU correlates with both the determinants of glucose tolerance, i.e. 
endogenous glucose production, and insulin secretion, and these correlations occur 
independently of BMI and insulin sensitivity, respectively. BFAU also correlates 
with insulin secretion. Moreover, a higher brain substrate uptake at baseline predicts 
worse glycemic control at follow-up after bariatric surgery.  
To better understand these results, we need to consider the term “central insulin 
resistance”, which has been coined previously by other study groups. Whereas the 
definition of systemic insulin resistance is based on tissue-level studies where several 
molecular defects have been established, the characterization of human brain 
metabolism relies on different in vivo neuroimaging methods, such as PET, fMRI, 
and MEG. Accordingly, other study groups have thus far defined brain insulin 
resistance as a blunted cerebrocortical insulin effect when MEG is applied (Tschritter 
et al., 2012) or as a decreased intranasal insulin-induced suppression of hypothalamic 
blood flow in fMRI (Kullmann et al., 2020). Along with these definitions, we think 
that the increased substrate uptake in brain PET studies could be considered as 
another aspect of brain insulin resistance. In any case, the results of the current thesis 
show brain insulin misresponse in the context of systemic insulin resistance. 
Unfortunately, multiple neuroimaging measures are seldom used within a single 
study, and in the absence of a ground truth measurement of brain insulin resistance, 
the integration of our PET results with the fMRI and MEG results of others is 
complicated. Thus, it would be important to assess the consistency of these measures 
(MEG, fMRI and [18F]FDG-PET) when applied to the same pool of subjects in order 
to reach a consensus on the definition of brain insulin resistance. This would be an 
important step in the better interpretation and understanding of this data.  
In this context, whereas it is now well established that brain substrate uptake is 
increased in case of obesity/insulin resistance, it is not known whether “brain insulin 
resistance” occurs earlier, later, or at the same time with systemic insulin resistance 
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(the chicken and the egg problem). Our centre has also tried to clarify this by 
studying young subjects at risk of obesity. The results should be available shortly. 
Moreover, based on the work for the current thesis, we have designed a new PET 
study, which addresses the question whether there is brain inflammation in the obese. 
If brain inflammation, in fact, is present, the need for a specific treatment – additional 
to the obvious and necessary treatments targeting weight loss – should be addressed. 
Another valid hypothesis regarding the reason for increased BGU in subjects 
with obesity/insulin resistance is BBB leakage. More specifically, inflammation, 
hyperglycemia, and obesity have all been described to disrupt the BBB (Hargrave et 
al., 2016; Shah et al., 2013). The endothelium cells and the astrocytes express the 
GLUT-1 transporter, and in the presence of a normally functional BBB, glucose 
transport into the brain would occur mainly through them. However, in an 
altered/disrupted BBB, plasma glucose would reach the CNS also through these 
“cracks” in the BBB, and thus neurons would be exposed to higher glucose levels, 
which, in turn, could put stress on the redox balance of the neurons. In the future, it 
would be, thus, interesting to study whether the increased BGU in obese/insulin 
resistant subjects is to be attributed to an increased BBB permeability with either 
[18F]FDG and a tracer that can be used to examine the permeability of the BBB (for 
instance the [68Ga]DTPA has been proposed) (Breuer et al., 2017) or with [18F]FDG 
and MRI with gadolinium (Breuer et al., 2017). 
Finally, whether this increased substrate uptake in the brain is also linked to any 
early cognitive impairment has not been thus far elucidated, and this is an aspect that 
we are currently also exploring. 
Even though the current results are probably still too distant from direct 
implementation in a clinical setup or clear new recommendations, the combination 
of these results and the new described information that should be available shortly 
(i.e. is there brain inflammation in human obesity, when does brain insulin resistance 
occur in the natural history of insulin resistance, is brain insulin resistance linked 
with cognitive dysfunction and worse metabolic outcome in the future) will 
hopefully help in developing novel ideas to be studied and ultimately may lead to 
new treatments in the battle against obesity.  
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7 Conclusions 
I. Insulin-stimulated brain glucose uptake is increased in the obese subjects 
compared to lean individuals and is positively associated with endogenous 
glucose production, markers of systemic inflammation, and levels of 
branched-chain and aromatic amino acids, and it also predicts plasma 
glucose levels at follow-up. These results suggest that the enhanced brain 
glucose uptake in obese subjects might not only be an epiphenomenon, 
but also part of the pathophysiology that leads to further deterioration in 
metabolic diseases.  
II. In subjects not affected by type 2 diabetes insulin-stimulated brain glucose 
uptake correlates positively with basal insulin secretion rate, total insulin 
output, and potentiation. In subjects affected by type 2 diabetes this pattern 
is altered since brain glucose uptake and insulin secretion do not correlate, 
but subjects with type 2 diabetes exhibit a clear negative correlation 
between BGU and potentiation. Brain fatty acid uptake also correlated 
differently with potentiation (negative correlation) and basal insulin 
secretion rate (positive correlation). Fasting BGU did not correlate with 
BISR. These results suggest that only in conditions where brain substrate 
uptake is increased in insulin resistance (insulin-stimulated state regarding 
BGU, and fasting state for BFAU), brain substrate uptake correlates with 
the parameters of β-cell function and that these correlations depend on the 
glucose tolerance status of the examined subjects. Even though correlations 
do not show cause-effect, these data suggest that also in humans the brain 
may be involved in the control of insulin secretion.  
III. Brain fatty acid uptake is increased in morbidly obese women compared 
to lean women; and six months after bariatric surgery, BFAU remains 
increased. Contrary to our hypothesis, BFAU did not correlate with the 
hypothalamus/amygdala signal ratio, which has been described to depict 
hypothalamic inflammation. However, better techniques are needed in 
order to address whether brain inflammation occurs in human obesity. 
Finally, brain fatty acid uptake at baseline predicts worse glycemic control 
at two years of follow-up. 
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